{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T14:48:13Z","timestamp":1791557293527,"version":"4.3.4"},"reference-count":449,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2014,3,28]],"date-time":"2014-03-28T00:00:00Z","timestamp":1395964800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"DOI":"10.1007\/s40263-014-0157-3","type":"journal-article","created":{"date-parts":[[2014,3,27]],"date-time":"2014-03-27T10:06:31Z","timestamp":1395914791000},"source":"Crossref","is-referenced-by-count":100,"title":["The Effects of Novel and Newly Approved Antipsychotics on Serum Prolactin Levels: A Comprehensive Review"],"prefix":"10.1007","author":[{"given":"J.","family":"Peuskens","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Pani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Detraux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"De Hert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,3,28]]},"reference":[{"issue":"1","key":"157_CR1","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1210\/jcem-67-1-116","volume":"67","author":"JD Veldhuis","year":"1988","unstructured":"Veldhuis JD, Johnson ML. Operating characteristics of the hypothalamo-pituitary-gonadal axis in men: circadian, ultradian, and pulsatile release of prolactin and its temporal coupling with luteinizing hormone. J Clin Endocrinol Metab. 1988;67(1):116\u201323.","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"157_CR2","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S0531-5565(99)00078-9","volume":"35","author":"M Llovera","year":"2000","unstructured":"Llovera M, Touraine P, Kelly PA, et al. Involvement of prolactin in breast cancer: redefining the molecular targets. Exp Gerontol. 2000;35(1):41\u201351.","journal-title":"Exp Gerontol"},{"issue":"5","key":"157_CR3","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1046\/j.1524-4741.2002.08506.x","volume":"8","author":"M Nicol","year":"2002","unstructured":"Nicol M, Willis C, Yiangou C, et al. Relationship between serum prolactin levels and histology of benign and malignant breast lesions: a detailed study of 153 consecutive cases. Breast J. 2002;8(5):281\u20135.","journal-title":"Breast J"},{"issue":"2 Suppl","key":"157_CR4","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1177\/0269216307087148","volume":"22","author":"P Fitzgerald","year":"2008","unstructured":"Fitzgerald P, Dinan TG. Prolactin and dopamine: what is the connection? A review article. J Psychopharmacol. 2008;22(2 Suppl):12\u20139.","journal-title":"J Psychopharmacol"},{"issue":"Pt 4","key":"157_CR5","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1258\/acb.2010.010025","volume":"47","author":"CJ Bushe","year":"2010","unstructured":"Bushe CJ, Bradley A, Pendlebury J. A review of hyperprolactinaemia and severe mental illness: are there implications for clinical biochemistry? Ann Clin Biochem. 2010;47(Pt 4):292\u2013300.","journal-title":"Ann Clin Biochem"},{"issue":"5 Suppl","key":"157_CR6","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1177\/0269881112442016","volume":"26","author":"J Cookson","year":"2012","unstructured":"Cookson J, Hodgson R, Wildgust HJ. Prolactin, hyperprolactinaemia and antipsychotic treatment: a review and lessons for treatment of early psychosis. J Psychopharmacol. 2012;26(5 Suppl):42\u201351.","journal-title":"J Psychopharmacol"},{"issue":"59","key":"157_CR7","first-page":"315","volume":"11","author":"EM Jacobson","year":"2011","unstructured":"Jacobson EM, Hugo ER, Borcherding DC, et al. Prolactin in breast and prostate cancer: molecular and genetic perspectives. Discov Med. 2011;11(59):315\u201324.","journal-title":"Discov Med"},{"issue":"1","key":"157_CR8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1677\/JOE-10-0069","volume":"206","author":"S Bernichtein","year":"2010","unstructured":"Bernichtein S, Touraine P, Goffin V. New concepts in prolactin biology. J Endocrinol. 2010;206(1):1\u201311.","journal-title":"J Endocrinol"},{"issue":"4","key":"157_CR9","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1517\/14740338.2011.560112","volume":"10","author":"SM Graham","year":"2011","unstructured":"Graham SM, Howgate D, Anderson W, et al. Risk of osteoporosis and fracture incidence in patients on antipsychotic medication. Expert Opin Drug Saf. 2011;10(4):575\u2013602.","journal-title":"Expert Opin Drug Saf"},{"issue":"7","key":"157_CR10","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1093\/jnci\/91.7.629","volume":"91","author":"SE Hankinson","year":"1999","unstructured":"Hankinson SE, Willett WC, Michaud DS, et al. Plasma prolactin levels and subsequent risk of breast cancer in postmenopausal women. J Natl Cancer Inst. 1999;91(7):629\u201334.","journal-title":"J Natl Cancer Inst"},{"issue":"3","key":"157_CR11","doi-asserted-by":"crossref","first-page":"163","DOI":"10.3109\/10401230209147453","volume":"14","author":"M Hamner","year":"2002","unstructured":"Hamner M. The effects of atypical antipsychotics on serum prolactin levels. Ann Clin Psychiatry. 2002;14(3):163\u201373.","journal-title":"Ann Clin Psychiatry"},{"issue":"9","key":"157_CR12","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1016\/S0024-3205(02)01775-7","volume":"71","author":"AM Meaney","year":"2002","unstructured":"Meaney AM, O\u2019Keane V. Prolactin and schizophrenia: clinical consequences of hyperprolactinaemia. Life Sci. 2002;71(9):979\u201392.","journal-title":"Life Sci"},{"issue":"2","key":"157_CR13","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1185\/030079903125002865","volume":"20","author":"M Hummer","year":"2004","unstructured":"Hummer M, Huber J. Hyperprolactinaemia and antipsychotic therapy in schizophrenia. Curr Med Res Opin. 2004;20(2):189\u201397.","journal-title":"Curr Med Res Opin"},{"issue":"10","key":"157_CR14","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1038\/ncpendmet0270","volume":"2","author":"V Goffin","year":"2006","unstructured":"Goffin V, Touraine P, Culler MD, et al. Drug Insight: prolactin-receptor antagonists, a novel approach to treatment of unresolved systemic and local hyperprolactinemia? Nat Clin Pract Endocrinol Metab. 2006;2(10):571\u201381.","journal-title":"Nat Clin Pract Endocrinol Metab"},{"issue":"Suppl","key":"157_CR15","doi-asserted-by":"crossref","first-page":"S67","DOI":"10.1016\/S0920-9964(98)00158-3","volume":"35","author":"RG Petty","year":"1999","unstructured":"Petty RG. Prolactin and antipsychotic medications: mechanism of action. Schizophr Res. 1999;35(Suppl):S67\u201373.","journal-title":"Schizophr Res"},{"issue":"6","key":"157_CR16","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1097\/jcp.0b013e31815ac4e5","volume":"27","author":"M Byerly","year":"2007","unstructured":"Byerly M, Suppes T, Tran QV, et al. Clinical implications of antipsychotic-induced hyperprolactinemia in patients with schizophrenia spectrum or bipolar spectrum disorders: recent developments and current perspectives. J Clin Psychopharmacol. 2007;27(6):639\u201361.","journal-title":"J Clin Psychopharmacol"},{"issue":"5","key":"157_CR17","first-page":"929","volume":"3","author":"D Torre La","year":"2007","unstructured":"La Torre D, Falorni A. Pharmacological causes of hyperprolactinemia. Ther Clin Risk Manag. 2007;3(5):929\u201351.","journal-title":"Ther Clin Risk Manag"},{"issue":"8","key":"157_CR18","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1517\/17425255.2013.791283","volume":"9","author":"V Voicu","year":"2013","unstructured":"Voicu V, Medvedovici A, Ranetti AE, et al. Drug-induced hypo- and hyperprolactinemia: mechanisms, clinical and therapeutic consequences. Expert Opin Drug Metab Toxicol. 2013;9(8):955\u201368.","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"4","key":"157_CR19","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1152\/physrev.2000.80.4.1523","volume":"80","author":"ME Freeman","year":"2000","unstructured":"Freeman ME, Kanyicska B, Lerant A, et al. Prolactin: structure, function, and regulation of secretion. Physiol Rev. 2000;80(4):1523\u2013631.","journal-title":"Physiol Rev"},{"issue":"Suppl 1","key":"157_CR20","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S0306-4530(02)00112-9","volume":"28","author":"U Halbreich","year":"2003","unstructured":"Halbreich U, Kinon BJ, Gilmore JA, et al. Elevated prolactin levels in patients with schizophrenia: mechanisms and related adverse effects. Psychoneuroendocrinology. 2003;28(Suppl 1):53\u201367.","journal-title":"Psychoneuroendocrinology"},{"issue":"5","key":"157_CR21","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1038\/sj.npp.1300412","volume":"29","author":"AB Emiliano","year":"2004","unstructured":"Emiliano AB, Fudge JL. From galactorrhea to osteopenia: rethinking serotonin-prolactin interactions. Neuropsychopharmacology. 2004;29(5):833\u201346.","journal-title":"Neuropsychopharmacology"},{"issue":"8","key":"157_CR22","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1017\/S003329170800319X","volume":"38","author":"N Bergemann","year":"2008","unstructured":"Bergemann N, Parzer P, Mundt C, et al. High bone turnover but normal bone mineral density in women suffering from schizophrenia. Psychol Med. 2008;38(8):1195\u2013201.","journal-title":"Psychol Med"},{"issue":"3","key":"157_CR23","doi-asserted-by":"crossref","first-page":"209","DOI":"10.2165\/00023210-199810030-00005","volume":"10","author":"MB Hamner","year":"1998","unstructured":"Hamner MB, Arana GW. Hyperprolactinaemia in antipsychotic-treated patients. Guidelines for avoidance and management. CNS Drugs. 1998;10(3):209\u201322.","journal-title":"CNS Drugs"},{"issue":"1","key":"157_CR24","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1159\/000116117","volume":"88","author":"DB Radl","year":"2008","unstructured":"Radl DB, Z\u00e1rate S, Jaita G, et al. Apoptosis of lactotrophs induced by D2 receptor activation is estrogen dependent. Neuroendocrinology. 2008;88(1):43\u201352.","journal-title":"Neuroendocrinology"},{"issue":"3","key":"157_CR25","first-page":"249","volume":"37","author":"J Tuomisto","year":"1985","unstructured":"Tuomisto J, M\u00e4nnist\u00f6 P. Neurotransmitter regulation of anterior pituitary hormones. Pharmacol Rev. 1985;37(3):249\u2013332.","journal-title":"Pharmacol Rev"},{"key":"157_CR26","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1192\/bjp.185.2.147","volume":"185","author":"RM Young","year":"2004","unstructured":"Young RM, Lawford BR, Barnes M, et al. Prolactin levels in antipsychotic treatment of patients with schizophrenia carrying the DRD2*A1 allele. Br J Psychiatry. 2004;185:147\u201351.","journal-title":"Br J Psychiatry"},{"key":"157_CR27","first-page":"140","volume":"28","author":"R Knegtering","year":"2004","unstructured":"Knegtering R, Castelein S, Bruggeman R. Vaak seksuele functiestoornissen door antipsychotica, vooral bij prolactineverhoging. Resultaten van een aantal vergelijkende onderzoeken. Tijdschrift Voor Seksuologie. 2004;28:140\u20136.","journal-title":"Tijdschrift Voor Seksuologie"},{"issue":"Suppl. 4","key":"157_CR28","first-page":"11","volume":"154","author":"American Psychiatric Association","year":"1997","unstructured":"American Psychiatric Association. Schizophrenia. Am J Psychiatry. 1997;154(Suppl. 4):11\u201325.","journal-title":"Am J Psychiatry"},{"issue":"8","key":"157_CR29","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.4065\/80.8.1050","volume":"80","author":"ME Molitch","year":"2005","unstructured":"Molitch ME. Medication-induced hyperprolactinemia. Mayo Clin Proc. 2005;80(8):1050\u20137.","journal-title":"Mayo Clin Proc"},{"key":"157_CR30","unstructured":"Knegtering H (2003) Antipsychotic treatment and sexual functioning: rol of prolactin. Proefschrift ter verkrijging van het doctoraat in de Medische Wetenschappen aan de Rijksuniversiteit Groningen. http:\/\/irs.ub.rug.nl\/ppn\/254939104 ."},{"issue":"1","key":"157_CR31","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1007\/BF02246407","volume":"126","author":"EF Coccaro","year":"1996","unstructured":"Coccaro EF, Kavoussi RJ, Oakes M, et al. 5-HT2a\/2c receptor blockade by amesergide fully attenuates prolactin response to d-fenfluramine challenge in physically healthy human subjects. Psychopharmacology (Berl). 1996;126(1):24\u201330.","journal-title":"Psychopharmacology (Berl)"},{"issue":"44","key":"157_CR32","doi-asserted-by":"crossref","first-page":"14630","DOI":"10.1523\/JNEUROSCI.5412-09.2010","volume":"30","author":"Y Xu","year":"2010","unstructured":"Xu Y, Jones JE, Lauzon DA, Anderson JG, Balthasar N, Heisler LK, Zinn AR, Lowell BB, Elmquist JK. A serotonin and melanocortin circuit mediates d-fenfluramine anorexia. J Neurosci. 2010;30(44):14630\u20134.","journal-title":"J Neurosci"},{"issue":"2","key":"157_CR33","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.yhbeh.2011.10.012","volume":"61","author":"KS Murnane","year":"2012","unstructured":"Murnane KS, Kimmel HL, Rice KC, et al. The neuropharmacology of prolactin secretion elicited by 3,4-methylenedioxymethamphetamine (\u201cecstasy\u201d): a concurrent microdialysis and plasma analysis study. Horm Behav. 2012;61(2):181\u201390.","journal-title":"Horm Behav"},{"issue":"3","key":"157_CR34","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1210\/en.2006-1198","volume":"148","author":"A Papageorgiou","year":"2007","unstructured":"Papageorgiou A, Denef C. Estradiol induces expression of 5-hydroxytryptamine (5-HT) 4, 5-HT5, and 5-HT6 receptor messenger ribonucleic acid in rat anterior pituitary cell aggregates and allows prolactin release via the 5-HT4 receptor. Endocrinology. 2007;148(3):1384\u201395.","journal-title":"Endocrinology"},{"issue":"1\u20132","key":"157_CR35","first-page":"203","volume":"73","author":"LD Kar Van de","year":"1996","unstructured":"Van de Kar LD, Rittenhouse PA, Li Q, et al. Serotonergic regulation of renin and prolactin secretion. Behav Brain Res. 1996;73(1\u20132):203\u20138.","journal-title":"Behav Brain Res"},{"issue":"5","key":"157_CR36","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1159\/000054381","volume":"68","author":"JA Balsa","year":"1998","unstructured":"Balsa JA, S\u00e1nchez-Franco F, Pazos F, et al. Direct action of serotonin on prolactin, growth hormone, corticotropin and luteinizing hormone release in cocultures of anterior and posterior pituitary lobes: autocrine and\/or paracrine action of vasoactive intestinal peptide. Neuroendocrinology. 1998;68(5):326\u201333.","journal-title":"Neuroendocrinology"},{"issue":"10","key":"157_CR37","doi-asserted-by":"crossref","first-page":"3572","DOI":"10.1523\/JNEUROSCI.21-10-03572.2001","volume":"21","author":"LD Kar Van de","year":"2001","unstructured":"Van de Kar LD, Javed A, Zhang Y, et al. 5-HT2A receptors stimulate ACTH, corticosterone, oxytocin, renin, and prolactin release and activate hypothalamic CRF and oxytocin-expressing cells. J Neurosci. 2001;21(10):3572\u20139.","journal-title":"J Neurosci"},{"issue":"7","key":"157_CR38","doi-asserted-by":"crossref","first-page":"2928","DOI":"10.1210\/endo.136.7.7540544","volume":"136","author":"C Breton","year":"1995","unstructured":"Breton C, Pechoux C, Morel G, et al. Oxytocin receptor messenger ribonucleic acid: characterization, regulation, and cellular localization in the rat pituitary gland. Endocrinology. 1995;136(7):2928\u201336.","journal-title":"Endocrinology"},{"issue":"2","key":"157_CR39","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1210\/endo-126-2-728","volume":"126","author":"RJ Mogg","year":"1990","unstructured":"Mogg RJ, Samson WK. Interactions of dopaminergic and peptidergic factors in the control of prolactin release. Endocrinology. 1990;126(2):728\u201335.","journal-title":"Endocrinology"},{"issue":"4","key":"157_CR40","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1210\/endo-126-4-1981","volume":"126","author":"IE Wanke","year":"1990","unstructured":"Wanke IE, Rorstad OP. Receptors for vasoactive intestinal peptide in rat anterior pituitary glands: localization of binding to lactotropes. Endocrinology. 1990;126(4):1981\u20138.","journal-title":"Endocrinology"},{"issue":"2","key":"157_CR41","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1210\/endo-124-2-812","volume":"124","author":"WK Samson","year":"1989","unstructured":"Samson WK, Bianchi R, Mogg RJ, et al. Oxytocin mediates the hypothalamic action of vasoactive intestinal peptide to stimulate prolactin secretion. Endocrinology. 1989;124(2):812\u20139.","journal-title":"Endocrinology"},{"issue":"2","key":"157_CR42","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1210\/endo.133.2.8344205","volume":"133","author":"PA Rittenhouse","year":"1993","unstructured":"Rittenhouse PA, Levy AD, Li Q, et al. Neurons in the hypothalamic paraventricular nucleus mediate the serotonergic stimulation of prolactin secretion via 5-HT1c\/2 receptors. Endocrinology. 1993;133(2):661\u20137.","journal-title":"Endocrinology"},{"issue":"1\u20132","key":"157_CR43","first-page":"277","volume":"73","author":"G Bagdy","year":"1996","unstructured":"Bagdy G. Role of the hypothalamic paraventricular nucleus in 5-HT1A, 5-HT2A and 5-HT2C receptor-mediated oxytocin, prolactin and ACTH\/corticosterone responses. Behav Brain Res. 1996;73(1\u20132):277\u201380.","journal-title":"Behav Brain Res"},{"issue":"2","key":"157_CR44","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/0006-8993(86)90841-3","volume":"364","author":"J Kiss","year":"1986","unstructured":"Kiss J, Hal\u00e1sz B. Synaptic connections between serotoninergic axon terminals and tyrosine hydroxylase-immunoreactive neurons in the arcuate nucleus of the rat hypothalamus. A combination of electron microscopic autoradiography and immunocytochemistry. Brain Res. 1986;364(2):284\u201394.","journal-title":"Brain Res"},{"issue":"2","key":"157_CR45","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1046\/j.1365-2826.2001.00612.x","volume":"13","author":"SJ Mirkes","year":"2001","unstructured":"Mirkes SJ, Bethea CL. Oestrogen, progesterone and serotonin converge on GABAergic neurones in the monkey hypothalamus. J Neuroendocrinol. 2001;13(2):182\u201392.","journal-title":"J Neuroendocrinol"},{"issue":"20","key":"157_CR46","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.2165\/00003495-200464200-00003","volume":"64","author":"PM Haddad","year":"2004","unstructured":"Haddad PM, Wieck A. Antipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and management. Drugs. 2004;64(20):2291\u2013314.","journal-title":"Drugs"},{"issue":"5","key":"157_CR47","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1073\/pnas.95.5.2325","volume":"95","author":"T-Y Chun","year":"1998","unstructured":"Chun T-Y, Gregg D, Sarkar DK, et al. Differential regulation by estrogens of growth and prolactin synthesis in pituitary cells suggests that only a small pool of estrogen receptors is required for growth. PNAS. 1998;95(5):2325\u201330.","journal-title":"PNAS"},{"issue":"6","key":"157_CR48","doi-asserted-by":"crossref","first-page":"2530","DOI":"10.1152\/japplphysiol.00681.2003","volume":"95","author":"Y Yokoyama","year":"2003","unstructured":"Yokoyama Y, Kitchens WC, Toth B, et al. Upregulation of hepatic prolactin receptor gene expression by 17\u03b2-estradiol following trauma-hemorrhage. J Appl Physiol. 2003;95(6):2530\u20136.","journal-title":"J Appl Physiol"},{"issue":"2","key":"157_CR49","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1097\/JCP.0b013e31820e4832","volume":"31","author":"T Veselinovi\u0107","year":"2011","unstructured":"Veselinovi\u0107 T, Schorn H, Vernaleken IB, et al. Impact of different antidopaminergic mechanisms on the dopaminergic control of prolactin secretion. J Clin Psychopharmacol. 2011;31(2):214\u201320.","journal-title":"J Clin Psychopharmacol"},{"issue":"3","key":"157_CR50","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1055\/s-0029-1241197","volume":"42","author":"CI Messini","year":"2010","unstructured":"Messini CI, Dafopoulos K, Chalvatzas N, et al. Effect of ghrelin and thyrotropin-releasing hormone on prolactin secretion in normal women. Horm Metab Res. 2010;42(3):204\u20138.","journal-title":"Horm Metab Res"},{"issue":"4","key":"157_CR51","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1007\/BF03347085","volume":"34","author":"CI Messini","year":"2011","unstructured":"Messini CI, Dafopoulos K, Chalvatzas N, et al. Effect of ghrelin and metoclopramide on prolactin secretion in normal women. J Endocrinol Invest. 2011;34(4):276\u20139.","journal-title":"J Endocrinol Invest"},{"key":"157_CR52","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1159\/000346054","volume":"25","author":"A Benso","year":"2013","unstructured":"Benso A, Calvi E, Gramaglia E, Olivetti I, Tomelini M, Ghigo E, Broglio F. Other than growth hormone neuroendocrine actions of ghrelin. Endocr Dev. 2013;25:59\u201368.","journal-title":"Endocr Dev"},{"issue":"3","key":"157_CR53","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s00737-002-0002-4","volume":"5","author":"JH Zhang-Wong","year":"2002","unstructured":"Zhang-Wong JH, Seeman MV. Antipsychotic drugs, menstrual regularity and osteoporosis risk. Arch Womens Ment Health. 2002;5(3):93\u20138.","journal-title":"Arch Womens Ment Health"},{"issue":"21","key":"157_CR54","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1056\/NEJMcp025334","volume":"349","author":"JA Schlechte","year":"2003","unstructured":"Schlechte JA. Clinical practice. Prolactinoma. N Engl J Med. 2003;349(21):2035\u201341.","journal-title":"N Engl J Med"},{"issue":"2 Suppl","key":"157_CR55","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1177\/0269881107087373","volume":"22","author":"L Citrome","year":"2008","unstructured":"Citrome L. Current guidelines and their recommendations for prolactin monitoring in psychosis. J Psychopharmacol. 2008;22(2 Suppl):90\u20137.","journal-title":"J Psychopharmacol"},{"key":"157_CR56","unstructured":"Peuskens J, editor. A literature review of \u201cProlactin in schizophrenia\u201d. Clear perspectives: management issues in schizophrenia, vol. 1, no. 3 (1997)."},{"issue":"Suppl 2","key":"157_CR57","doi-asserted-by":"crossref","first-page":"S108","DOI":"10.1016\/j.euroneuro.2008.02.004","volume":"18","author":"AL Montejo","year":"2008","unstructured":"Montejo AL. Prolactin awareness: an essential consideration for physical health in schizophrenia. Eur Neuropsychopharmacol. 2008;18(Suppl 2):S108\u201314.","journal-title":"Eur Neuropsychopharmacol"},{"issue":"2","key":"157_CR58","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/0165-1781(88)90046-7","volume":"25","author":"PJ Brown","year":"1988","unstructured":"Brown PJ, Cleghorn JM, Brown GM, et al. Seasonal variations in prolactin levels in schizophrenia. Psychiatry Res. 1988;25(2):157\u201362.","journal-title":"Psychiatry Res"},{"issue":"4","key":"157_CR59","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1093\/clinchem\/46.4.551","volume":"46","author":"AH Garde","year":"2000","unstructured":"Garde AH, Hansen AM, Skovgaard LT, et al. Seasonal and biological variation of blood concentrations of total cholesterol, dehydroepiandrosterone sulfate, hemoglobin A(1c), IgA, prolactin, and free testosterone in healthy women. Clin Chem. 2000;46(4):551\u20139.","journal-title":"Clin Chem"},{"issue":"4","key":"157_CR60","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1111\/j.1479-828X.2011.01321.x","volume":"51","author":"MJ Tanner","year":"2011","unstructured":"Tanner MJ, Hadlow NC, Wardrop R. Variation of female prolactin levels with menopausal status and phase of menstrual cycle. Aust N Z J Obstet Gynaecol. 2011;51(4):321\u20134.","journal-title":"Aust N Z J Obstet Gynaecol"},{"key":"157_CR61","doi-asserted-by":"crossref","unstructured":"Rosenbloom AL. Hyperprolactinemia with antipsychotic drugs in children and adolescents. Int J Pediatr Endocrinol. 2010; pii: 159402.","DOI":"10.1186\/1687-9856-2010-159402"},{"issue":"2","key":"157_CR62","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s11102-008-0107-5","volume":"11","author":"J Chahal","year":"2008","unstructured":"Chahal J, Schlechte J. Hyperprolactinemia. Pituitary. 2008;11(2):141\u20136.","journal-title":"Pituitary"},{"issue":"5","key":"157_CR63","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1177\/0269881110379289","volume":"25","author":"P Mackin","year":"2011","unstructured":"Mackin P, Waton A, Nulkar A, et al. Prolactin and smoking status in antipsychotic-treated patients. J Psychopharmacol. 2011;25(5):698\u2013703.","journal-title":"J Psychopharmacol"},{"issue":"2","key":"157_CR64","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.psychres.2013.04.026","volume":"209","author":"X Zhang","year":"2013","unstructured":"Zhang X, Bu R, Sha W, et al. Serum prolactin and smoking status in chronic antipsychotic-treated male patients with schizophrenia. Psychiatry Res. 2013;209(2):239\u201341.","journal-title":"Psychiatry Res"},{"issue":"2","key":"157_CR65","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.pnpbp.2010.12.025","volume":"35","author":"C Ohta","year":"2011","unstructured":"Ohta C, Yasui-Furukori N, Furukori H, et al. The effect of smoking status on the plasma concentration of prolactin already elevated by risperidone treatment in schizophrenia patients. Prog Neuropsychopharmacol Biol Psychiatry. 2011;35(2):573\u20136.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"issue":"2 Suppl","key":"157_CR66","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1177\/0269881107088435","volume":"22","author":"C Bushe","year":"2008","unstructured":"Bushe C, Shaw M, Peveler RC. A review of the association between antipsychotic use and hyperprolactinaemia. J Psychopharmacol. 2008;22(2 Suppl):46\u201355.","journal-title":"J Psychopharmacol"},{"issue":"2 Suppl","key":"157_CR67","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1177\/0269881107087346","volume":"22","author":"RC Peveler","year":"2008","unstructured":"Peveler RC, Branford D, Citrome L, et al. Antipsychotics and hyperprolactinaemia: clinical recommendations. J Psychopharmacol. 2008;22(2 Suppl):98\u2013103.","journal-title":"J Psychopharmacol"},{"issue":"1","key":"157_CR68","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1186\/1471-244X-13-214","volume":"13","author":"DL Kelly","year":"2013","unstructured":"Kelly DL, Wehring HJ, Earl AK, Sullivan K, Dickerson FB, Feldman S, McMahon RP, Buchanan RW, Warfel D, Keller WR, Fischer BA, Shim JC. Treating symptomatic hyperprolactinemia in women with schizophrenia: presentation of the ongoing DAAMSEL clinical trial (Dopamine partial Agonist, Aripiprazole, for the Management of Symptomatic ELevated prolactin). BMC Psychiatry. 2013;13(1):214.","journal-title":"BMC Psychiatry"},{"key":"157_CR69","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.pnpbp.2013.05.010","volume":"45","author":"T Tsuboi","year":"2013","unstructured":"Tsuboi T, Bies RR, Suzuki T, et al. Hyperprolactinemia and estimated dopamine D2 receptor occupancy in patients with schizophrenia: analysis of the CATIE data. Prog Neuropsychopharmacol Biol Psychiatry. 2013;45:178\u201382.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"issue":"5","key":"157_CR70","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1001\/archgenpsychiatry.2011.1508","volume":"69","author":"B Geller","year":"2012","unstructured":"Geller B, Luby JL, Joshi P, et al. A randomized controlled trial of risperidone, lithium, or divalproex sodium for initial treatment of bipolar I disorder, manic or mixed phase, children and adolescents. Arch Gen Psychiatry. 2012;69(5):515\u201328.","journal-title":"Arch Gen Psychiatry"},{"issue":"3","key":"157_CR71","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1097\/YIC.0b013e32835281ef","volume":"27","author":"L Citrome","year":"2012","unstructured":"Citrome L, Cucchiaro J, Sarma K, et al. Long-term safety and tolerability of lurasidone in schizophrenia: a 12-month, double-blind, active-controlled study. Int Clin Psychopharmacol. 2012;27(3):165\u201376.","journal-title":"Int Clin Psychopharmacol"},{"issue":"1","key":"157_CR72","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.pnpbp.2011.11.016","volume":"37","author":"T Kikuchi","year":"2012","unstructured":"Kikuchi T, Iwamoto K, Sasada K, et al. Sexual dysfunction and hyperprolactinemia in Japanese schizophrenic patients taking antipsychotics. Prog Neuropsychopharmacol Biol Psychiatry. 2012;37(1):26\u201332.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"issue":"6","key":"157_CR73","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1111\/j.1440-1819.2012.02391.x","volume":"66","author":"G Nagai","year":"2012","unstructured":"Nagai G, Mihara K, Nakamura A, et al. Prolactin concentrations during aripiprazole treatment in relation to sex, plasma drugs concentrations and genetic polymorphisms of dopamine D2 receptor and cytochrome P450 2D6 in Japanese patients with schizophrenia. Psychiatry Clin Neurosci. 2012;66(6):518\u201324.","journal-title":"Psychiatry Clin Neurosci"},{"issue":"6","key":"157_CR74","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1097\/JCP.0b013e318272688b","volume":"32","author":"R P\u00e9rez-Iglesias","year":"2012","unstructured":"P\u00e9rez-Iglesias R, Mata I, Mart\u00ednez-Garc\u00eda O, et al. Long-term effect of haloperidol, olanzapine, and risperidone on plasma prolactin levels in patients with first-episode psychosis. J Clin Psychopharmacol. 2012;32(6):804\u20138.","journal-title":"J Clin Psychopharmacol"},{"issue":"8","key":"157_CR75","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1002\/hup.1250","volume":"26","author":"N Sugawara","year":"2011","unstructured":"Sugawara N, Yasui-Furukori N, Fujii A, et al. No association between bone mass and prolactin levels among patients with schizophrenia. Hum Psychopharmacol. 2011;26(8):596\u2013601.","journal-title":"Hum Psychopharmacol"},{"issue":"2","key":"157_CR76","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1093\/schbul\/sbp037","volume":"37","author":"KP Grootens","year":"2011","unstructured":"Grootens KP, van Veelen NM, Peuskens J, et al. Ziprasidone vs olanzapine in recent-onset schizophrenia and schizoaffective disorder: results of an 8-week double-blind randomized controlled trial. Schizophr Bull. 2011;37(2):352\u201361.","journal-title":"Schizophr Bull"},{"issue":"4","key":"157_CR77","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1016\/j.pnpbp.2011.02.001","volume":"35","author":"H Li","year":"2011","unstructured":"Li H, Rui Q, Ning X, et al. A comparative study of paliperidone palmitate and risperidone long-acting injectable therapy in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2011;35(4):1002\u20138.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"issue":"5","key":"157_CR78","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1177\/0269881110372817","volume":"25","author":"S Gopal","year":"2011","unstructured":"Gopal S, Vijapurkar U, Lim P, et al. A 52-week open-label study of the safety and tolerability of paliperidone palmitate in patients with schizophrenia. J Psychopharmacol. 2011;25(5):685\u201397.","journal-title":"J Psychopharmacol"},{"issue":"7","key":"157_CR79","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1016\/j.pnpbp.2010.02.019","volume":"34","author":"J Aston","year":"2010","unstructured":"Aston J, Rechsteiner E, Bull N, Borgwardt S, Gschwandtner U, Riecher-R\u00f6ssler A. Hyperprolactinaemia in early psychosis\u2014not only due to antipsychotics. Prog Neuropsychopharmacol Biol Psychiatry. 2010;34(7):1342\u20134.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"issue":"9","key":"157_CR80","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.4088\/JCP.08m04307yel","volume":"71","author":"R Arakawa","year":"2010","unstructured":"Arakawa R, Okumura M, Ito H, et al. Positron emission tomography measurement of dopamine D2 receptor occupancy in the pituitary and cerebral cortex: relation to antipsychotic-induced hyperprolactinemia. J Clin Psychiatry. 2010;71(9):1131\u20137.","journal-title":"J Clin Psychiatry"},{"issue":"7","key":"157_CR81","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1177\/0269881108101783","volume":"24","author":"C Bushe","year":"2010","unstructured":"Bushe C, Sniadecki J, Bradley AJ, et al. Comparison of metabolic and prolactin variables from a six-month randomised trial of olanzapine and quetiapine in schizophrenia. J Psychopharmacol. 2010;24(7):1001\u20139.","journal-title":"J Psychopharmacol"},{"issue":"3","key":"157_CR82","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1097\/JCP.0b013e3181a289cb","volume":"29","author":"L Citrome","year":"2009","unstructured":"Citrome L, Stauffer VL, Chen L, et al. Olanzapine plasma concentrations after treatment with 10, 20, and 40\u00a0mg\/d in patients with schizophrenia: an analysis of correlations with efficacy, weight gain, and prolactin concentration. J Clin Psychopharmacol. 2009;29(3):278\u201383.","journal-title":"J Clin Psychopharmacol"},{"issue":"1","key":"157_CR83","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1111\/j.1440-1819.2008.01907.x","volume":"63","author":"JS Kwon","year":"2009","unstructured":"Kwon JS, Jang JH, Kang DH, et al. Long-term efficacy and safety of aripiprazole in patients with schizophrenia, schizophreniform disorder, or schizoaffective disorder: 26-week prospective study. Psychiatry Clin Neurosci. 2009;63(1):73\u201381.","journal-title":"Psychiatry Clin Neurosci"},{"issue":"1","key":"157_CR84","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1097\/CHI.0b013e3181900404","volume":"48","author":"L Kryzhanovskaya","year":"2009","unstructured":"Kryzhanovskaya L, Schulz SC, McDougle C, et al. Olanzapine versus placebo in adolescents with schizophrenia: a 6-week, randomized, double-blind, placebo-controlled trial. J Am Acad Child Adolesc Psychiatry. 2009;48(1):60\u201370.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"5","key":"157_CR85","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1097\/WNF.0b013e31819a68b5","volume":"32","author":"SW Kim","year":"2009","unstructured":"Kim SW, Shin IS, Kim JM, et al. Effectiveness of switching to aripiprazole from atypical antipsychotics in patients with schizophrenia. Clin Neuropharmacol. 2009;32(5):243\u20139.","journal-title":"Clin Neuropharmacol"},{"issue":"2\u20133","key":"157_CR86","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.schres.2008.09.019","volume":"107","author":"MJ Byerly","year":"2009","unstructured":"Byerly MJ, Marcus RN, Tran QV, et al. Effects of aripiprazole on prolactin levels in subjects with schizophrenia during cross-titration with risperidone or olanzapine: analysis of a randomized, open-label study. Schizophr Res. 2009;107(2\u20133):218\u201322.","journal-title":"Schizophr Res"},{"issue":"1","key":"157_CR87","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.psyneuen.2008.08.015","volume":"34","author":"B Konarzewska","year":"2009","unstructured":"Konarzewska B, Wo\u0142czy\u0144ski S, Szulc A, et al. Effect of risperidone and olanzapine on reproductive hormones, psychopathology and sexual functioning in male patients with schizophrenia. Psychoneuroendocrinology. 2009;34(1):129\u201339.","journal-title":"Psychoneuroendocrinology"},{"key":"157_CR88","doi-asserted-by":"crossref","first-page":"47","DOI":"10.2147\/NDT.S4766","volume":"5","author":"H Liu-Seifert","year":"2009","unstructured":"Liu-Seifert H, Kinon BJ, Tennant CJ, et al. Sexual dysfunction in patients with schizophrenia treated with conventional antipsychotics or risperidone. Neuropsychiatr Dis Treat. 2009;5:47\u201354.","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"7","key":"157_CR89","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/j.psyneuen.2009.01.013","volume":"34","author":"M Bruggen van","year":"2009","unstructured":"van Bruggen M, van Amelsvoort T, Wouters L, et al. Sexual dysfunction and hormonal changes in first episode psychosis patients on olanzapine or risperidone. Psychoneuroendocrinology. 2009;34(7):989\u201395.","journal-title":"Psychoneuroendocrinology"},{"issue":"2","key":"157_CR90","doi-asserted-by":"crossref","first-page":"293","DOI":"10.4088\/JCP.08l04509","volume":"70","author":"A Tschoner","year":"2009","unstructured":"Tschoner A, Engl J, Rettenbacher MA, et al. Is second-generation antipsychotic-induced hyperprolactinemia due to biologically active prolactin or to biologically inactive macroprolactin? Results from a prospective study. J Clin Psychiatry. 2009;70(2):293\u20134.","journal-title":"J Clin Psychiatry"},{"issue":"5","key":"157_CR91","doi-asserted-by":"crossref","first-page":"817","DOI":"10.4088\/JCP.v69n0515","volume":"69","author":"HY Meltzer","year":"2008","unstructured":"Meltzer HY, Bobo WV, Nuamah IF, et al. Efficacy and tolerability of oral paliperidone extended-release tablets in the treatment of acute schizophrenia: pooled data from three 6-week, placebo-controlled studies. J Clin Psychiatry. 2008;69(5):817\u201329.","journal-title":"J Clin Psychiatry"},{"issue":"6","key":"157_CR92","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1097\/YIC.0b013e328314e1f3","volume":"23","author":"R Emsley","year":"2008","unstructured":"Emsley R, Berwaerts J, Eerdekens M, et al. Efficacy and safety of oral paliperidone extended-release tablets in the treatment of acute schizophrenia: pooled data from three 52-week open-label studies. Int Clin Psychopharmacol. 2008;23(6):343\u201356.","journal-title":"Int Clin Psychopharmacol"},{"issue":"9618","key":"157_CR93","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1016\/S0140-6736(08)60486-9","volume":"371","author":"RS Kahn","year":"2008","unstructured":"Kahn RS, Fleischhacker WW, Boter H, et al. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet. 2008;371(9618):1085\u201397.","journal-title":"Lancet"},{"issue":"8","key":"157_CR94","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.1016\/j.pnpbp.2008.09.016","volume":"32","author":"ML Lu","year":"2008","unstructured":"Lu ML, Shen WW, Chen CH. Time course of the changes in antipsychotic-induced hyperprolactinemia following the switch to aripiprazole. Prog Neuropsychopharmacol Biol Psychiatry. 2008;32(8):1978\u201381.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"157_CR95","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/1471-244X-8-95","volume":"8","author":"L Hanssens","year":"2008","unstructured":"Hanssens L, L\u2019Italien G, Loze JY, et al. The effect of antipsychotic medication on sexual function and serum prolactin levels in community-treated schizophrenic patients: results from the Schizophrenia Trial of Aripiprazole (STAR) study (NCT00237913). BMC Psychiatry. 2008;8:95.","journal-title":"BMC Psychiatry"},{"issue":"3","key":"157_CR96","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1097\/JCP.0b013e318172473c","volume":"28","author":"HN Yuan","year":"2008","unstructured":"Yuan HN, Wang CY, Sze CW, et al. A randomized, crossover comparison of herbal medicine and bromocriptine against risperidone-induced hyperprolactinemia in patients with schizophrenia. J Clin Psychopharmacol. 2008;28(3):264\u2013370.","journal-title":"J Clin Psychopharmacol"},{"issue":"3","key":"157_CR97","doi-asserted-by":"crossref","first-page":"385","DOI":"10.4088\/JCP.v69n0307","volume":"69","author":"T Kishimoto","year":"2008","unstructured":"Kishimoto T, Watanabe K, Shimada N, et al. Antipsychotic-induced hyperprolactinemia inhibits the hypothalamo-pituitary-gonadal axis and reduces bone mineral density in male patients with schizophrenia. J Clin Psychiatry. 2008;69(3):385\u201391.","journal-title":"J Clin Psychiatry"},{"issue":"3","key":"157_CR98","doi-asserted-by":"crossref","first-page":"361","DOI":"10.4088\/JCP.v68n0302","volume":"68","author":"OD Howes","year":"2007","unstructured":"Howes OD, Wheeler MJ, Pilowsky LS, et al. Sexual function and gonadal hormones in patients taking antipsychotic treatment for schizophrenia or schizoaffective disorder. J Clin Psychiatry. 2007;68(3):361\u20137.","journal-title":"J Clin Psychiatry"},{"issue":"5","key":"157_CR99","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.psyneuen.2005.12.006","volume":"31","author":"BJ Kinon","year":"2006","unstructured":"Kinon BJ, Ahl J, Liu-Seifert H, et al. Improvement in hyperprolactinemia and reproductive comorbidities in patients with schizophrenia switched from conventional antipsychotics or risperidone to olanzapine. Psychoneuroendocrinology. 2006;31(5):577\u201388.","journal-title":"Psychoneuroendocrinology"},{"issue":"3","key":"157_CR100","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.psyneuen.2005.08.010","volume":"31","author":"DL Kelly","year":"2006","unstructured":"Kelly DL, Conley RR. A randomized double-blind 12-week study of quetiapine, risperidone or fluphenazine on sexual functioning in people with schizophrenia. Psychoneuroendocrinology. 2006;31(3):340\u20136.","journal-title":"Psychoneuroendocrinology"},{"issue":"5","key":"157_CR101","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1176\/appi.ajp.162.5.947","volume":"162","author":"N Schooler","year":"2005","unstructured":"Schooler N, Rabinowitz J, Davidson M, et al. Risperidone and haloperidol in first-episode psychosis: a long-term randomized trial. Am J Psychiatry. 2005;162(5):947\u201353.","journal-title":"Am J Psychiatry"},{"issue":"1","key":"157_CR102","doi-asserted-by":"crossref","first-page":"57","DOI":"10.4088\/JCP.v65n0109","volume":"65","author":"J Volavka","year":"2004","unstructured":"Volavka J, Czobor P, Cooper TB, et al. Prolactin levels in schizophrenia and schizoaffective disorder patients treated with clozapine, olanzapine, risperidone, or haloperidol. J Clin Psychiatry. 2004;65(1):57\u201361.","journal-title":"J Clin Psychiatry"},{"issue":"12","key":"157_CR103","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.4088\/JCP.v65n1207","volume":"65","author":"DE Addington","year":"2004","unstructured":"Addington DE, Pantelis C, Dineen M, et al. Efficacy and tolerability of ziprasidone versus risperidone in patients with acute exacerbation of schizophrenia or schizoaffective disorder: an 8-week, double-blind, multicenter trial. J Clin Psychiatry. 2004;65(12):1624\u201333.","journal-title":"J Clin Psychiatry"},{"key":"157_CR104","doi-asserted-by":"crossref","unstructured":"Bobes J, Timdahl K. Quetiapine: placebo-level prolactin and low levels of sexual dysfunction. Poster presented at the 17th European College of Neuropsychopharmacology, Stockholm; 2004.","DOI":"10.1016\/S0924-977X(04)80251-7"},{"issue":"11","key":"157_CR105","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.4088\/JCP.v65n1108","volume":"65","author":"J Montgomery","year":"2004","unstructured":"Montgomery J, Winterbottom E, Jessani M, et al. Prevalence of hyperprolactinemia in schizophrenia: association with typical and atypical antipsychotic treatment. J Clin Psychiatry. 2004;65(11):1491\u20138.","journal-title":"J Clin Psychiatry"},{"issue":"2","key":"157_CR106","doi-asserted-by":"crossref","first-page":"187","DOI":"10.4088\/JCP.v65n0207","volume":"65","author":"R Cavallaro","year":"2004","unstructured":"Cavallaro R, Cocchi F, Angelone SM, et al. Cabergoline treatment of risperidone-induced hyperprolactinemia: a pilot study. J Clin Psychiatry. 2004;65(2):187\u201390.","journal-title":"J Clin Psychiatry"},{"issue":"Suppl 2","key":"157_CR107","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S0306-4530(02)00127-0","volume":"28","author":"BJ Kinon","year":"2003","unstructured":"Kinon BJ, Ahl J, Liu-Seifert H, et al. Prevalence of hyperprolactinemia in schizophrenic patients treated with conventional antipsychotic medications or risperidone. Psychoneuroendocrinology. 2003;28(Suppl 2):55\u201368.","journal-title":"Psychoneuroendocrinology"},{"issue":"7","key":"157_CR108","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1001\/archpsyc.60.7.681","volume":"60","author":"SG Potkin","year":"2003","unstructured":"Potkin SG, Saha AR, Kujawa MJ, et al. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. Arch Gen Psychiatry. 2003;60(7):681\u201390.","journal-title":"Arch Gen Psychiatry"},{"issue":"1","key":"157_CR109","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/S0165-1781(02)00123-3","volume":"111","author":"CM Canuso","year":"2002","unstructured":"Canuso CM, Goldstein JM, Wojcik J, et al. Antipsychotic medication, prolactin elevation, and ovarian function in women with schizophrenia and schizoaffective disorder. Psychiatry Res. 2002;111(1):11\u201320.","journal-title":"Psychiatry Res"},{"issue":"7","key":"157_CR110","doi-asserted-by":"crossref","first-page":"541","DOI":"10.4088\/JCP.v62n07a07","volume":"62","author":"D Aizenberg","year":"2001","unstructured":"Aizenberg D, Modai I, Landa A, et al. Comparison of sexual dysfunction in male schizophrenic patients maintained on treatment with classic antipsychotics versus clozapine. J Clin Psychiatry. 2001;62(7):541\u20134.","journal-title":"J Clin Psychiatry"},{"issue":"1","key":"157_CR111","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0306-4530(00)00034-2","volume":"26","author":"TJ Huber","year":"2001","unstructured":"Huber TJ, Rollnik J, Wilhelms J, et al. Estradiol levels in psychotic disorders. Psychoneuroendocrinology. 2001;26(1):27\u201335.","journal-title":"Psychoneuroendocrinology"},{"issue":"9","key":"157_CR112","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1016\/S0149-2918(00)80086-7","volume":"22","author":"SR David","year":"2000","unstructured":"David SR, Taylor CC, Kinon BJ, et al. The effects of olanzapine, risperidone, and haloperidol on plasma prolactin levels in patients with schizophrenia. Clin Ther. 2000;22(9):1085\u201396.","journal-title":"Clin Ther"},{"issue":"4","key":"157_CR113","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1111\/j.1600-0447.1997.tb10162.x","volume":"96","author":"J Peuskens","year":"1997","unstructured":"Peuskens J, Link CG. A comparison of quetiapine and chlorpromazine in the treatment of schizophrenia. Acta Psychiatr Scand. 1997;96(4):265\u201373.","journal-title":"Acta Psychiatr Scand"},{"issue":"1","key":"157_CR114","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S0920-9964(97)00036-4","volume":"26","author":"AM Crawford","year":"1997","unstructured":"Crawford AM, Beasley CM Jr, Tollefson GD. The acute and long-term effect of olanzapine compared with placebo and haloperidol on serum prolactin concentrations. Schizophr Res. 1997;26(1):41\u201354.","journal-title":"Schizophr Res"},{"issue":"2 Suppl","key":"157_CR115","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1177\/0269881107086516","volume":"22","author":"J Walters","year":"2008","unstructured":"Walters J, Jones I. Clinical questions and uncertainty\u2014prolactin measurement in patients with schizophrenia and bipolar disorder. J Psychopharmacol. 2008;22(2 Suppl):82\u20139.","journal-title":"J Psychopharmacol"},{"issue":"5","key":"157_CR116","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/S0033-3182(10)70718-0","volume":"51","author":"S Ali","year":"2010","unstructured":"Ali S, Miller KK, Freudenreich O. Management of psychosis associated with a prolactinoma: case report and review of the literature. Psychosomatics. 2010;51(5):370\u20136.","journal-title":"Psychosomatics"},{"key":"157_CR117","author":"AG Alkabbani","year":"2013","unstructured":"Alkabbani AG, Mon SY, Hatipoglu B, Kennedy L, Faiman C, Weil RJ, Hamrahian AH. Is a stable or decreasing prolactin level in a patient with prolactinoma a surrogate marker for lack of tumor growth? Pituitary. 2013;. doi: 10.1007\/s11102-013-0473-5 .","journal-title":"Pituitary"},{"issue":"1","key":"157_CR118","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.fertnstert.2005.01.102","volume":"84","author":"A Bayrak","year":"2005","unstructured":"Bayrak A, Saadat P, Mor E, Chong L, Paulson RJ, Sokol RZ. Pituitary imaging is indicated for the evaluation of hyperprolactinemia. Fertil Steril. 2005;84(1):181\u20135.","journal-title":"Fertil Steril"},{"key":"157_CR119","unstructured":"http:\/\/www.pituitary.org\/disorders\/prolactinomas.aspx . Accessed 17 Sep 2013."},{"issue":"9","key":"157_CR120","first-page":"21","volume":"9","author":"GT Arcari","year":"2012","unstructured":"Arcari GT, Mendes AK, Sothern RB. A risperidone-induced prolactinoma resolved when a woman with schizoaffective disorder switched to ziprasidone: a case report. Innov Clin Neurosci. 2012;9(9):21\u20134.","journal-title":"Innov Clin Neurosci"},{"issue":"2","key":"157_CR121","doi-asserted-by":"crossref","first-page":"209.e1\u20133","DOI":"10.1016\/j.genhosppsych.2011.07.004","volume":"34","author":"R Broekhof","year":"2012","unstructured":"Broekhof R, Gosselink MJ, Pijl H, et al. The effect of aripiprazole and quinagolide, a dopamine agonist, in a patient with symptomatic pituitary prolactinoma and chronic psychosis. Gen Hosp Psychiatry. 2012;34(2):209.e1\u20133.","journal-title":"Gen Hosp Psychiatry"},{"issue":"6","key":"157_CR122","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1592\/phco.26.6.748","volume":"26","author":"A Szarfman","year":"2006","unstructured":"Szarfman A, Tonning JM, Levine JG, et al. Atypical antipsychotics and pituitary tumors: a pharmacovigilance study. Pharmacotherapy. 2006;26(6):748\u201358.","journal-title":"Pharmacotherapy"},{"issue":"2","key":"157_CR123","doi-asserted-by":"crossref","first-page":"60","DOI":"10.9758\/cpn.2013.11.2.60","volume":"11","author":"BJ Lee","year":"2013","unstructured":"Lee BJ, Lee SJ, Kim MK, et al. Effect of aripiprazole on cognitive function and hyperprolactinemia in patients with schizophrenia treated with risperidone. Clin Psychopharmacol Neurosci. 2013;11(2):60\u20136.","journal-title":"Clin Psychopharmacol Neurosci"},{"issue":"2","key":"157_CR124","first-page":"12","volume":"10","author":"D Coppola","year":"2013","unstructured":"Coppola D, Thiagarajah S, Qiu H, et al. Regarding \u201cA risperidone-induced prolactinoma resolved when a woman with schizoaffective disorder switched to ziprasidone: a case report\u201d. Innov Clin Neurosci. 2013;10(2):12\u20136.","journal-title":"Innov Clin Neurosci"},{"key":"157_CR125","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/1744-859X-8-5","volume":"8","author":"FD Gianfrancesco","year":"2009","unstructured":"Gianfrancesco FD, Pandina G, Mahmoud R, et al. Potential bias in testing for hyperprolactinemia and pituitary tumors in risperidone-treated patients: a claims-based study. Ann Gen Psychiatry. 2009;8:5.","journal-title":"Ann Gen Psychiatry"},{"issue":"6","key":"157_CR126","first-page":"575","volume":"169","author":"O Serri","year":"2003","unstructured":"Serri O, Chik CL, Ur E, et al. Diagnosis and management of hyperprolactinemia. CMAJ. 2003;169(6):575\u201381.","journal-title":"CMAJ"},{"issue":"1","key":"157_CR127","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1097\/00004714-199902000-00011","volume":"19","author":"DL Kleinberg","year":"1999","unstructured":"Kleinberg DL, Davis JM, De Coster R, et al. Prolactin levels and adverse events in patients treated with risperidone. J Clin Psychopharmacol. 1999;19(1):57\u201361.","journal-title":"J Clin Psychopharmacol"},{"issue":"6","key":"157_CR128","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/j.psyneuen.2008.02.008","volume":"33","author":"H Knegtering","year":"2008","unstructured":"Knegtering H, van den Bosch R, Castelein S, et al. Are sexual side effects of prolactin-raising antipsychotics reducible to serum prolactin? Psychoneuroendocrinology. 2008;33(6):711\u20137.","journal-title":"Psychoneuroendocrinology"},{"issue":"3","key":"157_CR129","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1097\/JCP.0b013e3182199bcc","volume":"31","author":"P Malik","year":"2011","unstructured":"Malik P, Kemmler G, Hummer M, EUFEST Study Group, et al. Sexual dysfunction in first-episode schizophrenia patients: results from European First Episode Schizophrenia Trial. J Clin Psychopharmacol. 2011;31(3):274\u201380.","journal-title":"J Clin Psychopharmacol"},{"issue":"12 Suppl","key":"157_CR130","first-page":"1095","volume":"44","author":"BM Biller","year":"1999","unstructured":"Biller BM. Diagnostic evaluation of hyperprolactinemia. J Reprod Med. 1999;44(12 Suppl):1095\u20139.","journal-title":"J Reprod Med"},{"issue":"2 Suppl","key":"157_CR131","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1177\/0269881107088436","volume":"22","author":"C Bushe","year":"2008","unstructured":"Bushe C, Yeomans D, Floyd T, et al. Categorical prevalence and severity of hyperprolactinaemia in two UK cohorts of patients with severe mental illness during treatment with antipsychotics. J Psychopharmacol. 2008;22(2 Suppl):56\u201362.","journal-title":"J Psychopharmacol"},{"issue":"3","key":"157_CR132","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.pnpbp.2010.02.014","volume":"34","author":"N Yasui-Furukori","year":"2010","unstructured":"Yasui-Furukori N, Saito M, Nakagami T, et al. Gender-specific prolactin response to antipsychotic treatments with risperidone and olanzapine and its relationship to drug concentrations in patients with acutely exacerbated schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2010;34(3):537\u201340.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"issue":"3","key":"157_CR133","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1002\/hup.1110","volume":"25","author":"N Yasui-Furukori","year":"2010","unstructured":"Yasui-Furukori N, Furukori H, Sugawara N, et al. Prolactin fluctuation over the course of a day during treatments with three atypical antipsychotics in schizophrenic patients. Hum Psychopharmacol. 2010;25(3):236\u201342.","journal-title":"Hum Psychopharmacol"},{"issue":"6","key":"157_CR134","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1016\/j.pnpbp.2008.05.006","volume":"32","author":"N Yasui-Furukori","year":"2008","unstructured":"Yasui-Furukori N, Saito M, Tsuchimine S, et al. Association between dopamine-related polymorphisms and plasma concentrations of prolactin during risperidone treatment in schizophrenic patients. Prog Neuropsychopharmacol Biol Psychiatry. 2008;32(6):1491\u20135.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"issue":"6","key":"157_CR135","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1016\/j.pnpbp.2007.04.021","volume":"31","author":"N Yasui-Furukori","year":"2007","unstructured":"Yasui-Furukori N, Tsuchimine S, Saito M, et al. Association between major Multidrug Resistance 1 (MDR1) gene polymorphisms and plasma concentration of prolactin during risperidone treatment in schizophrenic patients. Prog Neuropsychopharmacol Biol Psychiatry. 2007;31(6):1230\u20134.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"issue":"8","key":"157_CR136","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1016\/j.pnpbp.2006.05.011","volume":"30","author":"K Sawamura","year":"2006","unstructured":"Sawamura K, Suzuki Y, Fukui N, et al. Gender differences in prolactin elevation induced by olanzapine in Japanese drug-na\u00efve schizophrenic patients. Prog Neuropsychopharmacol Biol Psychiatry. 2006;30(8):1511\u20134.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"issue":"4","key":"157_CR137","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1111\/j.1600-0447.1977.tb00229.x","volume":"56","author":"B Wode-Helgodt","year":"1977","unstructured":"Wode-Helgodt B, Eneroth P, Fyr\u00f6 B, et al. Effect of chlorpromazine treatment on prolactin levels in cerebrospinal fluid and plasma of psychotic patients. Acta Psychiatr Scand. 1977;56(4):280\u201393.","journal-title":"Acta Psychiatr Scand"},{"issue":"9","key":"157_CR138","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1111\/j.1440-1681.1992.tb00511.x","volume":"19","author":"A Kuruvilla","year":"1992","unstructured":"Kuruvilla A, Peedicayil J, Srikrishna G, et al. A study of serum prolactin levels in schizophrenia: comparison of males and females. Clin Exp Pharmacol Physiol. 1992;19(9):603\u20136.","journal-title":"Clin Exp Pharmacol Physiol"},{"issue":"1","key":"157_CR139","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/S0006-3223(98)00125-5","volume":"45","author":"G Gr\u00fcnder","year":"1999","unstructured":"Gr\u00fcnder G, Wetzel H, Schl\u00f6sser R, et al. Neuroendocrine response to antipsychotics: effects of drug type and gender. Biol Psychiatry. 1999;45(1):89\u201397.","journal-title":"Biol Psychiatry"},{"issue":"Suppl 2","key":"157_CR140","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S0306-4530(02)00128-2","volume":"28","author":"BJ Kinon","year":"2003","unstructured":"Kinon BJ, Gilmore JA, Liu H, et al. Hyperprolactinemia in response to antipsychotic drugs: characterization across comparative clinical trials. Psychoneuroendocrinology. 2003;28(Suppl 2):69\u201382.","journal-title":"Psychoneuroendocrinology"},{"issue":"2","key":"157_CR141","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1097\/00004714-200204000-00002","volume":"22","author":"S Smith","year":"2002","unstructured":"Smith S, Wheeler MJ, Murray R, et al. The effects of antipsychotic-induced hyperprolactinaemia on the hypothalamic-pituitary-gonadal axis. J Clin Psychopharmacol. 2002;22(2):109\u201314.","journal-title":"J Clin Psychopharmacol"},{"issue":"4","key":"157_CR142","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1016\/j.pnpbp.2005.11.037","volume":"30","author":"BH Lee","year":"2006","unstructured":"Lee BH, Kim YK. The relationship between prolactin response and clinical efficacy of risperidone in acute psychotic inpatients. Prog Neuropsychopharmacol Biol Psychiatry. 2006;30(4):658\u201362.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"issue":"5","key":"157_CR143","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1097\/00131746-200309000-00003","volume":"9","author":"U Halbreich","year":"2003","unstructured":"Halbreich U, Kahn LS. Hyperprolactinemia and schizophrenia: mechanisms and clinical aspects. J Psychiatr Pract. 2003;9(5):344\u201353.","journal-title":"J Psychiatr Pract"},{"issue":"4","key":"157_CR144","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1089\/cap.1999.9.239","volume":"9","author":"M Wudarsky","year":"1999","unstructured":"Wudarsky M, Nicolson R, Hamburger SD, et al. Elevated prolactin in pediatric patients on typical and atypical antipsychotics. J Child Adolesc Psychopharmacol. 1999;9(4):239\u201345.","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"8","key":"157_CR145","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1097\/00004583-199908000-00011","volume":"38","author":"JA Frazier","year":"1999","unstructured":"Frazier JA, Meyer MC, Biederman J, et al. Risperidone treatment for juvenile bipolar disorder: a retrospective chart review. J Am Acad Child Adolesc Psychiatry. 1999;38(8):960\u20135.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"3","key":"157_CR146","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1097\/00004583-200003000-00010","volume":"39","author":"FR Sallee","year":"2000","unstructured":"Sallee FR, Kurlan R, Goetz CG, et al. Ziprasidone treatment of children and adolescents with Tourette\u2019s syndrome: a pilot study. J Am Acad Child Adolesc Psychiatry. 2000;39(3):292\u20139.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"1","key":"157_CR147","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1097\/00004583-200301000-00004","volume":"42","author":"MP Jordan","year":"2003","unstructured":"Jordan MP. Ziprasidone-associated galactorrhea in a female teenager. J Am Acad Child Adolesc Psychiatry. 2003;42(1):4\u20135.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"3","key":"157_CR148","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1089\/cap.2004.14.359","volume":"14","author":"M Pappagallo","year":"2004","unstructured":"Pappagallo M, Silva R. The effect of atypical antipsychotic agents on prolactin levels in children and adolescents. J Child Adolesc Psychopharmacol. 2004;14(3):359\u201371.","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"6","key":"157_CR149","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1089\/cap.2005.15.885","volume":"15","author":"JA Hellings","year":"2005","unstructured":"Hellings JA, Zarcone JR, Valdovinos MG, et al. Risperidone-induced prolactin elevation in a prospective study of children, adolescents, and adults with mental retardation and pervasive developmental disorders. J Child Adolesc Psychopharmacol. 2005;15(6):885\u201392.","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"2","key":"157_CR150","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1097\/01.jcp.0000203194.58087.9a","volume":"26","author":"L Holzer","year":"2006","unstructured":"Holzer L, Eap CB. Risperidone-induced symptomatic hyperprolactinaemia in adolescents. J Clin Psychopharmacol. 2006;26(2):167\u201371.","journal-title":"J Clin Psychopharmacol"},{"issue":"7","key":"157_CR151","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.4088\/JCP.v67n0714","volume":"67","author":"S Madhusoodanan","year":"2006","unstructured":"Madhusoodanan S, Moise D. Risperidone-induced hyperprolactinemia in adolescents: A case series. J Clin Psychiatry. 2006;67(7):1110\u20133.","journal-title":"J Clin Psychiatry"},{"issue":"8","key":"157_CR152","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1097\/01.chi.0000223312.48406.6e","volume":"45","author":"BL Handen","year":"2006","unstructured":"Handen BL, Hardan AY. Open-label, prospective trial of olanzapine in adolescents with subaverage intelligence and disruptive behavioral disorders. J Am Acad Child Adolesc Psychiatry. 2006;45(8):928\u201335.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"8","key":"157_CR153","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1016\/j.pnpbp.2009.08.009","volume":"33","author":"G Migliardi","year":"2009","unstructured":"Migliardi G, Spina E, D\u2019Arrigo C, et al. Short- and long-term effects on prolactin of risperidone and olanzapine treatments in children and adolescents. Prog Neuropsychopharmacol Biol Psychiatry. 2009;33(8):1496\u2013501.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"issue":"1","key":"157_CR154","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/YIC.0b013e3283320511","volume":"25","author":"HS Swadi","year":"2010","unstructured":"Swadi HS, Craig BJ, Pirwani NZ, et al. A trial of quetiapine compared with risperidone in the treatment of first onset psychosis among 15- to 18-year-old adolescents. Int Clin Psychopharmacol. 2010;25(1):1\u20136.","journal-title":"Int Clin Psychopharmacol"},{"issue":"2","key":"157_CR155","doi-asserted-by":"crossref","first-page":"179","DOI":"10.2165\/11585350-000000000-00000","volume":"71","author":"G Masi","year":"2011","unstructured":"Masi G, Liboni F. Management of schizophrenia in children and adolescents: focus on pharmacotherapy. Drugs. 2011;71(2):179\u2013208.","journal-title":"Drugs"},{"issue":"1","key":"157_CR156","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.ecl.2007.10.013","volume":"37","author":"T Mancini","year":"2008","unstructured":"Mancini T, Casanueva FF, Giustina A. Hyperprolactinemia and prolactinomas. Endocrinol Metab Clin North Am. 2008;37(1):67\u201399 vii.","journal-title":"Endocrinol Metab Clin North Am"},{"issue":"11","key":"157_CR157","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1001\/archpsyc.1978.01770350017001","volume":"35","author":"PM Schyve","year":"1978","unstructured":"Schyve PM, Smithline F, Meltzer HY. Neuroleptic-induced prolactin level elevation and breast cancer: an emerging clinical issue. Arch Gen Psychiatry. 1978;35(11):1291\u2013301.","journal-title":"Arch Gen Psychiatry"},{"key":"157_CR158","volume-title":"Endocrinology","author":"MD Bronstein","year":"2006","unstructured":"Bronstein MD. Disorders of prolactin secretion and prolactinomas. In: DeGroot LL, Jameson LJ, editors. Endocrinology, vol. 1. USA: Elsevier Saunders; 2006."},{"issue":"4","key":"157_CR159","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1002\/hup.1116","volume":"25","author":"S Madhusoodanan","year":"2010","unstructured":"Madhusoodanan S, Parida S, Jimenez C. Hyperprolactinemia associated with psychotropics\u2014a review. Hum Psychopharmacol. 2010;25(4):281\u201397.","journal-title":"Hum Psychopharmacol"},{"issue":"Suppl 2","key":"157_CR160","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/S0306-4530(02)00129-4","volume":"28","author":"U Naidoo","year":"2003","unstructured":"Naidoo U, Goff DC, Klibanski A. Hyperprolactinemia and bone mineral density: the potential impact of antipsychotic agents. Psychoneuroendocrinology. 2003;28(Suppl 2):97\u2013108.","journal-title":"Psychoneuroendocrinology"},{"issue":"3","key":"157_CR161","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.psychres.2004.01.010","volume":"127","author":"M Segal","year":"2004","unstructured":"Segal M, Avital A, Rojas M, et al. Serum prolactin levels in unmedicated first-episode and recurrent schizophrenia patients: a possible marker for the disease\u2019s subtypes. Psychiatry Res. 2004;127(3):227\u201335.","journal-title":"Psychiatry Res"},{"issue":"8","key":"157_CR162","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/S0006-3223(96)00222-3","volume":"41","author":"CM Mazure","year":"1997","unstructured":"Mazure CM, Quinlan DM, Bowers MB Jr. Recent life stressors and biological markers in newly admitted psychotic patients. Biol Psychiatry. 1997;41(8):865\u201370.","journal-title":"Biol Psychiatry"},{"issue":"3","key":"157_CR163","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/0006-3223(94)91147-9","volume":"35","author":"ML Rao","year":"1994","unstructured":"Rao ML, Gross G, Strebel B, et al. Circadian rhythm of tryptophan, serotonin, melatonin, and pituitary hormones in schizophrenia. Biol Psychiatry. 1994;35(3):151\u201363.","journal-title":"Biol Psychiatry"},{"issue":"10","key":"157_CR164","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1176\/ajp.144.10.1335","volume":"144","author":"NA Keks","year":"1987","unstructured":"Keks NA, Copolov DL, Singh BS. Abnormal prolactin response to haloperidol challenge in men with schizophrenia. Am J Psychiatry. 1987;144(10):1335\u20137.","journal-title":"Am J Psychiatry"},{"issue":"4","key":"157_CR165","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1001\/archpsyc.1974.01760160102021","volume":"31","author":"HY Meltzer","year":"1974","unstructured":"Meltzer HY, Sachar EJ, Frantz AG. Serum prolactin levels in unmedicated schizophrenic patients. Arch Gen Psychiatry. 1974;31(4):564\u20139.","journal-title":"Arch Gen Psychiatry"},{"issue":"1","key":"157_CR166","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.genm.2012.01.001","volume":"9","author":"E Tsigkaropoulou","year":"2012","unstructured":"Tsigkaropoulou E, Peppa M, Zompola C, et al. Hypogonadism due to hyperprolactinemia and subsequent first episode of psychosis. Gend Med. 2012;9(1):56\u201360.","journal-title":"Gend Med"},{"issue":"2","key":"157_CR167","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.pnpbp.2006.09.016","volume":"31","author":"M Segal","year":"2007","unstructured":"Segal M, Avital A, Berstein S, et al. Prolactin and estradiol serum levels in unmedicated male paranoid schizophrenia patients. Prog Neuropsychopharmacol Biol Psychiatry. 2007;31(2):378\u201382.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"issue":"1","key":"157_CR168","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.schres.2011.07.025","volume":"134","author":"C Garcia-Rizo","year":"2012","unstructured":"Garcia-Rizo C, Fernandez-Egea E, Oliveira C, et al. Prolactin concentrations in newly diagnosed, antipsychotic-na\u00efve patients with nonaffective psychosis. Schizophr Res. 2012;134(1):16\u20139.","journal-title":"Schizophr Res"},{"issue":"12","key":"157_CR169","doi-asserted-by":"crossref","first-page":"2571","DOI":"10.1017\/S0033291713000226","volume":"43","author":"A Riecher-R\u00f6ssler","year":"2013","unstructured":"Riecher-R\u00f6ssler A, Rybakowski JK, Pflueger MO, et al. Hyperprolactinemia in antipsychotic-naive patients with first-episode psychosis. Psychol Med. 2013;43(12):2571\u201382.","journal-title":"Psychol Med"},{"issue":"1","key":"157_CR170","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1159\/000329028","volume":"65","author":"JK Rybakowski","year":"2012","unstructured":"Rybakowski JK, Dmitrzak-Weglarz M, Kapelski P, et al. Functional \u22121149g\/t polymorphism of the prolactin gene in schizophrenia. Neuropsychobiology. 2012;65(1):41\u20134.","journal-title":"Neuropsychobiology"},{"issue":"Suppl 1","key":"157_CR171","doi-asserted-by":"crossref","first-page":"4","DOI":"10.4088\/JCP.10075su1.01","volume":"72","author":"R Tandon","year":"2011","unstructured":"Tandon R. Antipsychotics in the treatment of schizophrenia: an overview. J Clin Psychiatry. 2011;72(Suppl 1):4\u20138.","journal-title":"J Clin Psychiatry"},{"issue":"3","key":"157_CR172","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1159\/000329391","volume":"94","author":"M Doknic","year":"2011","unstructured":"Doknic M, Maric NP, Britvic D, et al. Bone remodeling, bone mass and weight gain in patients with stabilized schizophrenia in real-life conditions treated with long-acting injectable risperidone. Neuroendocrinology. 2011;94(3):246\u201354.","journal-title":"Neuroendocrinology"},{"issue":"4","key":"157_CR173","first-page":"428","volume":"32","author":"K Melkersson","year":"2011","unstructured":"Melkersson K, Berinder K, Hulting AL. Effect of antipsychotic-induced hyperprolactinemia on anthropometric measures, insulin sensitivity and lipid profile in patients with schizophrenia or related psychoses. Neuro Endocrinol Lett. 2011;32(4):428\u201336.","journal-title":"Neuro Endocrinol Lett"},{"issue":"1 Pt 1","key":"157_CR174","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/S0013-7006(06)76142-5","volume":"32","author":"T Haefliger","year":"2006","unstructured":"Haefliger T, Bonsack C. Atypical antipsychotics and sexual dysfunction: five case-reports associated with risperidone. Encephale. 2006;32(1 Pt 1):97\u2013105.","journal-title":"Encephale"},{"issue":"2","key":"157_CR175","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1017\/S1461145704005012","volume":"8","author":"M Dossenbach","year":"2005","unstructured":"Dossenbach M, Hodge A, Anders M, et al. Prevalence of sexual dysfunction in patients with schizophrenia: international variation and underestimation. Int J Neuropsychopharmacol. 2005;8(2):195\u2013201.","journal-title":"Int J Neuropsychopharmacol"},{"issue":"14","key":"157_CR176","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.2165\/00002018-200427140-00005","volume":"27","author":"P Toren","year":"2004","unstructured":"Toren P, Ratner S, Laor N, et al. Benefit-risk assessment of atypical antipsychotics in the treatment of schizophrenia and comorbid disorders in children and adolescents. Drug Saf. 2004;27(14):1135\u201356.","journal-title":"Drug Saf"},{"issue":"Suppl","key":"157_CR177","doi-asserted-by":"crossref","first-page":"S75","DOI":"10.1016\/S0920-9964(98)00159-5","volume":"35","author":"RA Dickson","year":"1999","unstructured":"Dickson RA, Glazer WM. Neuroleptic-induced hyperprolactinemia. Schizophr Res. 1999;35(Suppl):S75\u201386.","journal-title":"Schizophr Res"},{"issue":"4","key":"157_CR178","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1111\/j.1600-0447.2006.00897.x","volume":"115","author":"J Eberhard","year":"2007","unstructured":"Eberhard J, Lindstrom E, Holstad M, et al. Prolactin level during 5\u00a0years of risperidone treatment in patients with psychotic disorders. Acta Psychiatr Scand. 2007;115(4):268\u201376.","journal-title":"Acta Psychiatr Scand"},{"issue":"2 Suppl","key":"157_CR179","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1177\/0269881107088439","volume":"22","author":"V O\u2019Keane","year":"2008","unstructured":"O\u2019Keane V. Antipsychotic-induced hyperprolactinaemia, hypogonadism and osteoporosis in the treatment of schizophrenia. J Psychopharmacol. 2008;22(2 Suppl):70\u20135.","journal-title":"J Psychopharmacol"},{"issue":"10","key":"157_CR180","first-page":"851","volume":"11","author":"PA Marken","year":"1992","unstructured":"Marken PA, Haykal RF, Fisher JN. Management of psychotropic-induced hyperprolactinemia. Clin Pharm. 1992;11(10):851\u20136.","journal-title":"Clin Pharm"},{"issue":"3","key":"157_CR181","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/0165-1781(81)90078-0","volume":"5","author":"WA Brown","year":"1981","unstructured":"Brown WA, Laughren TP. Tolerance to the prolactin-elevating effect of neuroleptics. Psychiatry Res. 1981;5(3):317\u201322.","journal-title":"Psychiatry Res"},{"issue":"3","key":"157_CR182","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1001\/archpsyc.1976.01770030003001","volume":"33","author":"HY Meltzer","year":"1976","unstructured":"Meltzer HY, Fang VS. The effect of neuroleptics on serum prolactin in schizophrenic patients. Arch Gen Psychiatry. 1976;33(3):279\u201386.","journal-title":"Arch Gen Psychiatry"},{"key":"157_CR183","first-page":"177","volume-title":"Hormones, behaviour, and psychopathology","author":"HY Meltzer","year":"1976","unstructured":"Meltzer HY, Fang VS. Serum prolactin levels in schizophrenia\u2014effect of antipsychotic drugs: a preliminary report. In: Sachar EJ, editor. Hormones, behaviour, and psychopathology. New York: Raven Press; 1976. p. 177\u201390."},{"key":"157_CR184","first-page":"95","volume":"40","author":"Y Igarashi","year":"1985","unstructured":"Igarashi Y, Higuchi T, Toyoshima R, et al. Tolerance to prolactin secretion in the long-term treatment with neuroleptics in schizophrenia. Adv Biochem Psychopharmacol. 1985;40:95\u20138.","journal-title":"Adv Biochem Psychopharmacol"},{"key":"157_CR185","first-page":"59","volume":"40","author":"HY Meltzer","year":"1985","unstructured":"Meltzer HY. Long-term effects of neuroleptic drugs on the neuroendocrine system. Adv Biochem Psychopharmacol. 1985;40:59\u201368.","journal-title":"Adv Biochem Psychopharmacol"},{"issue":"5 Pt 1","key":"157_CR186","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/S0029-7844(98)00066-0","volume":"91","author":"M Spitzer","year":"1998","unstructured":"Spitzer M, Sajjad R, Benjamin F. Pattern of development of hyperprolactinemia after initiation of haloperidol therapy. Obstet Gynecol. 1998;91(5 Pt 1):693\u20135.","journal-title":"Obstet Gynecol"},{"issue":"1\u20133","key":"157_CR187","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.schres.2012.12.027","volume":"145","author":"Y Suzuki","year":"2013","unstructured":"Suzuki Y, Sugai T, Fukui N, et al. Differences in plasma prolactin levels in patients with schizophrenia treated on monotherapy with five second-generation antipsychotics. Schizophr Res. 2013;145(1\u20133):116\u20139.","journal-title":"Schizophr Res"},{"issue":"3","key":"157_CR188","first-page":"390","volume":"25","author":"HY Meltzer","year":"1989","unstructured":"Meltzer HY, Matsubara S, Lee JC. The ratios of serotonin2 and dopamine2 affinities differentiate atypical and typical antipsychotic drugs. Psychopharmacol Bull. 1989;25(3):390\u20132.","journal-title":"Psychopharmacol Bull"},{"issue":"1","key":"157_CR189","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1111\/j.1365-2265.1979.tb03033.x","volume":"10","author":"C Hagen","year":"1979","unstructured":"Hagen C, Pedersen PB, Jensen SB, et al. The effect of sulpiride induced hyperprolactinaemia on glucose tolerance and insulin secretion in normal subjects. Clin Endocrinol (Oxf). 1979;10(1):55\u201360.","journal-title":"Clin Endocrinol (Oxf)"},{"key":"157_CR190","doi-asserted-by":"crossref","first-page":"205","DOI":"10.2147\/DHPS.S6226","volume":"2","author":"MF Juruena","year":"2010","unstructured":"Juruena MF, de Sena EP, de Oliveira IR. Safety and tolerability of antipsychotics: focus on amisulpride. Drug Healthc Patient Saf. 2010;2:205\u201311.","journal-title":"Drug Healthc Patient Saf"},{"issue":"1","key":"157_CR191","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1111\/j.1440-1819.2011.02296.x","volume":"66","author":"BH Lee","year":"2012","unstructured":"Lee BH, Kang SG, Kim TW, et al. Hyperprolactinemia induced by low-dosage amisulpride in Korean psychiatric patients. Psychiatry Clin Neurosci. 2012;66(1):69\u201373.","journal-title":"Psychiatry Clin Neurosci"},{"issue":"6","key":"157_CR192","first-page":"419","volume":"25","author":"M Kopecek","year":"2004","unstructured":"Kopecek M, Bares M, Svarc J, et al. Hyperprolactinemia after low dose of amisulpride. Neuro Endocrinol Lett. 2004;25(6):419\u201322.","journal-title":"Neuro Endocrinol Lett"},{"issue":"4","key":"157_CR193","first-page":"320","volume":"26","author":"M Kopecek","year":"2005","unstructured":"Kopecek M, Bares M, Horacek J. Normalization of hyperprolactinaemia after withdrawal of a low dose of amisulpride. Neuro Endocrinol Lett. 2005;26(4):320.","journal-title":"Neuro Endocrinol Lett"},{"issue":"2","key":"157_CR194","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1111\/j.1365-2265.2010.03814.x","volume":"74","author":"RI Holt","year":"2011","unstructured":"Holt RI, Peveler RC. Antipsychotics and hyperprolactinaemia: mechanisms, consequences and management. Clin Endocrinol (Oxf). 2011;74(2):141\u20137.","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"6","key":"157_CR195","doi-asserted-by":"crossref","first-page":"e558","DOI":"10.4088\/JCP.13f08510","volume":"74","author":"C Andrade","year":"2013","unstructured":"Andrade C. Low-dose amisulpride and elevation in serum prolactin. J Clin Psychiatry. 2013;74(6):e558\u201360.","journal-title":"J Clin Psychiatry"},{"issue":"Suppl 2","key":"157_CR196","first-page":"97","volume":"30","author":"M Fric","year":"2003","unstructured":"Fric M, Laux G. Prolactin levels and symptoms of hyperprolactinemia in patients treated with amisulpride, risperidone, olanzapine and quetiapine. Psychiatr Prax. 2003;30(Suppl 2):97\u2013101.","journal-title":"Psychiatr Prax"},{"issue":"13","key":"157_CR197","doi-asserted-by":"crossref","first-page":"933","DOI":"10.2165\/00023210-200418130-00007","volume":"18","author":"K McKeage","year":"2004","unstructured":"McKeage K, Plosker GL. Amisulpride: a review of its use in the management of schizophrenia. CNS Drugs. 2004;18(13):933\u201356.","journal-title":"CNS Drugs"},{"issue":"1","key":"157_CR198","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.pnpbp.2006.07.006","volume":"31","author":"T Paparrigopoulos","year":"2007","unstructured":"Paparrigopoulos T, Liappas J, Tzavellas E, et al. Amisulpride-induced hyperprolactinemia is reversible following discontinuation. Prog Neuropsychopharmacol Biol Psychiatry. 2007;31(1):92\u20136.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"issue":"8","key":"157_CR199","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1002\/hup.1246","volume":"26","author":"YM Ahn","year":"2011","unstructured":"Ahn YM, Lee KY, Kim CE, et al. The acute and long-term effectiveness of amisulpride in patients with schizophrenia: results of a 12-month open-label prospective follow-up study. Hum Psychopharmacol. 2011;26(8):568\u201377.","journal-title":"Hum Psychopharmacol"},{"issue":"2","key":"157_CR200","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1055\/s-0031-1291175","volume":"45","author":"EY Kim","year":"2012","unstructured":"Kim EY, Kim SH, Lee NY, et al. Relationship between prolactin levels and subjective endocrine-related adverse effects in patients with schizophrenia receiving long-term treatment with amisulpride. Pharmacopsychiatry. 2012;45(2):57\u201363.","journal-title":"Pharmacopsychiatry"},{"issue":"4","key":"157_CR201","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1192\/bjp.bp.110.085670","volume":"199","author":"V Frighi","year":"2011","unstructured":"Frighi V, Stephenson MT, Morovat A, et al. Safety of antipsychotics in people with intellectual disability. Br J Psychiatry. 2011;199(4):289\u201395.","journal-title":"Br J Psychiatry"},{"issue":"15","key":"157_CR202","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.2165\/00003495-200464150-00010","volume":"64","author":"T Swainston Harrison","year":"2004","unstructured":"Swainston Harrison T, Perry CM. Aripiprazole: a review of its use in schizophrenia and schizoaffective disorder. Drugs. 2004;64(15):1715\u201336.","journal-title":"Drugs"},{"issue":"5","key":"157_CR203","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/S0149-2918(04)90066-5","volume":"26","author":"A DeLeon","year":"2004","unstructured":"DeLeon A, Patel NC, Crismon ML. Aripiprazole: a comprehensive review of its pharmacology, clinical efficacy, and tolerability. Clin Ther. 2004;26(5):649\u201366.","journal-title":"Clin Ther"},{"issue":"8","key":"157_CR204","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1016\/j.pnpbp.2004.06.020","volume":"28","author":"D Naber","year":"2004","unstructured":"Naber D, Lambert M. Aripiprazole: a new atypical antipsychotic with a different pharmacological mechanism. Prog Neuropsychopharmacol Biol Psychiatry. 2004;28(8):1213\u20139.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"issue":"6","key":"157_CR205","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.biopsych.2008.07.033","volume":"65","author":"WW Fleischhacker","year":"2009","unstructured":"Fleischhacker WW, McQuade RD, Marcus RN, et al. A double-blind, randomized comparative study of aripiprazole and olanzapine in patients with schizophrenia. Biol Psychiatry. 2009;65(6):510\u20137.","journal-title":"Biol Psychiatry"},{"key":"157_CR206","doi-asserted-by":"crossref","first-page":"319","DOI":"10.2147\/NDT.S13876","volume":"7","author":"RS McIntyre","year":"2011","unstructured":"McIntyre RS, Yoon J, Jerrell JM, et al. Aripiprazole for the maintenance treatment of bipolar disorder: a review of available evidence. Neuropsychiatr Dis Treat. 2011;7:319\u201323.","journal-title":"Neuropsychiatr Dis Treat"},{"key":"157_CR207","doi-asserted-by":"crossref","unstructured":"Belgamwar RB, El-Sayeh HG. Aripiprazole versus placebo for schizophrenia. Cochrane Database Syst Rev. 2011;(8):CD006622.","DOI":"10.1002\/14651858.CD006622.pub2"},{"issue":"1","key":"157_CR208","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1111\/j.1440-1819.2010.02156.x","volume":"65","author":"CY Chen","year":"2011","unstructured":"Chen CY, Lin TY, Wang CC, et al. Improvement of serum prolactin and sexual function after switching to aripiprazole from risperidone in schizophrenia: a case series. Psychiatry Clin Neurosci. 2011;65(1):95\u20137.","journal-title":"Psychiatry Clin Neurosci"},{"issue":"11","key":"157_CR209","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1586\/ern.11.151","volume":"11","author":"MH Park","year":"2011","unstructured":"Park MH, Han C, Pae CU, et al. Aripiprazole treatment for patients with schizophrenia: from acute treatment to maintenance treatment. Expert Rev Neurother. 2011;11(11):1541\u201352.","journal-title":"Expert Rev Neurother"},{"issue":"1","key":"157_CR210","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1111\/j.1440-1819.2009.02036.x","volume":"64","author":"H Takeuchi","year":"2010","unstructured":"Takeuchi H, Uchida H, Suzuki T, et al. Changes in metabolic parameters following a switch to aripiprazole in Japanese patients with schizophrenia: one-year follow-up study. Psychiatry Clin Neurosci. 2010;64(1):104\u20136.","journal-title":"Psychiatry Clin Neurosci"},{"issue":"1","key":"157_CR211","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1111\/j.1440-1819.2009.02039.x","volume":"64","author":"HY Lee","year":"2010","unstructured":"Lee HY, Ham BJ, Kang RH, et al. Trial of aripiprazole in the treatment of first-episode schizophrenia. Psychiatry Clin Neurosci. 2010;64(1):38\u201343.","journal-title":"Psychiatry Clin Neurosci"},{"issue":"1\u20132","key":"157_CR212","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.jad.2008.12.017","volume":"115","author":"ID Glick","year":"2009","unstructured":"Glick ID, Mankoski R, Eudicone JM, et al. The efficacy, safety, and tolerability of aripiprazole for the treatment of schizoaffective disorder: results from a pooled analysis of a sub-population of subjects from two randomized, double-blind, placebo-controlled, pivotal trials. J Affect Disord. 2009;115(1\u20132):18\u201326.","journal-title":"J Affect Disord"},{"issue":"3","key":"157_CR213","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1177\/0269881107082901","volume":"22","author":"A Mir","year":"2008","unstructured":"Mir A, Shivakumar K, Williamson RJ, et al. Change in sexual dysfunction with aripiprazole: a switching or add-on study. J Psychopharmacol. 2008;22(3):244\u201353.","journal-title":"J Psychopharmacol"},{"issue":"2","key":"157_CR214","doi-asserted-by":"crossref","first-page":"213","DOI":"10.4088\/JCP.v68n0206","volume":"68","author":"JM Kane","year":"2007","unstructured":"Kane JM, Meltzer HY, Carson WH Jr, et al. Aripiprazole for treatment-resistant schizophrenia: results of a multicenter, randomized, double-blind, comparison study versus perphenazine. J Clin Psychiatry. 2007;68(2):213\u201323.","journal-title":"J Clin Psychiatry"},{"issue":"2","key":"157_CR215","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s00213-006-0564-3","volume":"189","author":"WK Chrzanowski","year":"2006","unstructured":"Chrzanowski WK, Marcus RN, Torbeyns A, et al. Effectiveness of long-term aripiprazole therapy in patients with acutely relapsing or chronic, stable schizophrenia: a 52-week, open-label comparison with olanzapine. Psychopharmacology (Berl). 2006;189(2):259\u201366.","journal-title":"Psychopharmacology (Berl)"},{"issue":"4","key":"157_CR216","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/j.pnpbp.2006.02.001","volume":"30","author":"BH Lee","year":"2006","unstructured":"Lee BH. KimYK, Park SH. Using aripiprazole to resolve antipsychotic-induced symptomatic hyperprolactinemia: a pilot study. Prog Neuropsychopharmacol Biol Psychiatry. 2006;30(4):714\u20137.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"issue":"Suppl 18","key":"157_CR217","first-page":"47","volume":"65","author":"RD McQuade","year":"2004","unstructured":"McQuade RD, Stock E, Marcus R, et al. A comparison of weight change during treatment with olanzapine or aripiprazole: results from a randomized, double-blind study. J Clin Psychiatry. 2004;65(Suppl 18):47\u201356.","journal-title":"J Clin Psychiatry"},{"issue":"4","key":"157_CR218","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/s00213-002-1344-3","volume":"166","author":"DE Casey","year":"2003","unstructured":"Casey DE, Carson WH, Saha AR, Aripiprazole Study Group, et al. Switching patients to aripiprazole from other antipsychotic agents: a multicenter randomized study. Psychopharmacology (Berl). 2003;166(4):391\u20139.","journal-title":"Psychopharmacology (Berl)"},{"issue":"2\u20133","key":"157_CR219","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0920-9964(03)00050-1","volume":"61","author":"SR Marder","year":"2003","unstructured":"Marder SR, McQuade RD, Stock E, et al. Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials. Schizophr Res. 2003;61(2\u20133):123\u201336.","journal-title":"Schizophr Res"},{"issue":"9","key":"157_CR220","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.4088\/JCP.v64n0910","volume":"64","author":"TA Pigott","year":"2003","unstructured":"Pigott TA, Carson WH, Saha AR, et al. Aripiprazole for the prevention of relapse in stabilized patients with chronic schizophrenia: a placebo-controlled 26-week study. J Clin Psychiatry. 2003;64(9):1048\u201356.","journal-title":"J Clin Psychiatry"},{"issue":"9","key":"157_CR221","doi-asserted-by":"crossref","first-page":"763","DOI":"10.4088\/JCP.v63n0903","volume":"63","author":"JM Kane","year":"2002","unstructured":"Kane JM, Carson WH, Saha AR, et al. Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. J Clin Psychiatry. 2002;63(9):763\u201371.","journal-title":"J Clin Psychiatry"},{"issue":"4","key":"157_CR222","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1017\/S1461145703003651","volume":"6","author":"S Kasper","year":"2003","unstructured":"Kasper S, Lerman MN, McQuade RD, et al. Efficacy and safety of aripiprazole vs. haloperidol for long-term maintenance treatment following acute relapse of schizophrenia. Int J Neuropsychopharmacol. 2003;6(4):325\u201337.","journal-title":"Int J Neuropsychopharmacol"},{"issue":"7","key":"157_CR223","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.eurpsy.2007.03.002","volume":"22","author":"R Kerwin","year":"2007","unstructured":"Kerwin R, Millet B, Herman E, et al. A multicentre, randomized, naturalistic, open-label study between aripiprazole and standard of care in the management of community-treated schizophrenic patients Schizophrenia Trial of Aripiprazole: (STAR) study. Eur Psychiatry. 2007;22(7):433\u201343.","journal-title":"Eur Psychiatry"},{"key":"157_CR224","unstructured":"Byerly MJ, Pikalov A, Marcus RN, et al. Effects of aripiprazole on prolactin levels in patients with schizophrenia during cross titration with risperidone or olanzapine. Poster presented at the 160th annual meeting of the American Psychiatric Association, San Diego; 2007."},{"issue":"5","key":"157_CR225","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1097\/JCP.0b013e3181ee832d","volume":"30","author":"N Yasui-Furukori","year":"2010","unstructured":"Yasui-Furukori N, Furukori H, Sugawara N, et al. Dose-dependent effects of adjunctive treatment with aripiprazole on hyperprolactinemia induced by risperidone in female patients with schizophrenia. J Clin Psychopharmacol. 2010;30(5):596\u20139.","journal-title":"J Clin Psychopharmacol"},{"issue":"8","key":"157_CR226","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1016\/j.pnpbp.2010.08.012","volume":"34","author":"CK Chen","year":"2010","unstructured":"Chen CK, Huang YS, Ree SC, et al. Differential add-on effects of aripiprazole in resolving hyperprolactinemia induced by risperidone in comparison to benzamide antipsychotics. Prog Neuropsychopharmacol Biol Psychiatry. 2010;34(8):1495\u20139.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"issue":"10","key":"157_CR227","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.4088\/JCP.09m05154yel","volume":"70","author":"JM Kane","year":"2009","unstructured":"Kane JM, Correll CU, Goff DC, et al. A multicenter, randomized, double-blind, placebo-controlled, 16-week study of adjunctive aripiprazole for schizophrenia or schizoaffective disorder inadequately treated with quetiapine or risperidone monotherapy. J Clin Psychiatry. 2009;70(10):1348\u201357.","journal-title":"J Clin Psychiatry"},{"issue":"9","key":"157_CR228","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1176\/appi.ajp.2007.06071075","volume":"164","author":"JC Shim","year":"2007","unstructured":"Shim JC, Shin JG, Kelly DL, et al. Adjunctive treatment with a dopamine partial agonist, aripiprazole, for antipsychotic-induced hyperprolactinemia: a placebo-controlled trial. Am J Psychiatry. 2007;164(9):1404\u201310.","journal-title":"Am J Psychiatry"},{"key":"157_CR229","unstructured":"Findling RL, Auby P, Mallikaarjun S, et al. Tolerability of aripiprazole in the treatment of adolescents with schizophrenia. Poster presented at the 160th annual meeting of the American Psychiatric Association, San Diego; 2007."},{"issue":"8","key":"157_CR230","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1176\/appi.ajp.162.8.1542-a","volume":"162","author":"R Wahl","year":"2005","unstructured":"Wahl R, Ostroff R. Reversal of symptomatic hyperprolactinemia by aripiprazole. Am J Psychiatry. 2005;162(8):1542\u20133.","journal-title":"Am J Psychiatry"},{"issue":"4","key":"157_CR231","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1097\/JCP.0b013e3182970431","volume":"33","author":"MZ Ziadi Trives","year":"2013","unstructured":"Ziadi Trives MZ, Ll\u00e1cer JM, Escudero MA, et al. Effect of the addition of aripiprazole on hyperprolactinemia associated with risperidone long-acting injection. J Clin Psychopharmacol. 2013;33(4):538\u201341.","journal-title":"J Clin Psychopharmacol"},{"issue":"8","key":"157_CR232","doi-asserted-by":"crossref","first-page":"e70179","DOI":"10.1371\/journal.pone.0070179","volume":"8","author":"X Li","year":"2013","unstructured":"Li X, Tang Y, Wang C. Adjunctive aripiprazole versus placebo for antipsychotic-induced hyperprolactinemia: meta-analysis of randomized controlled trials. PLoS ONE. 2013;8(8):e70179.","journal-title":"PLoS ONE"},{"issue":"1","key":"157_CR233","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1017\/S1461145706007115","volume":"10","author":"M Paulzen","year":"2007","unstructured":"Paulzen M, Gr\u00fcnder G. Amisulpride-induced hyperprolactinaemia is not reversed by addition of aripiprazole. Int J Neuropsychopharmacol. 2007;10(1):149\u201351.","journal-title":"Int J Neuropsychopharmacol"},{"issue":"4","key":"157_CR234","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1093\/oxfordjournals.schbul.a007130","volume":"30","author":"DL Kelly","year":"2004","unstructured":"Kelly DL, Conley RR. Sexuality and schizophrenia: a review. Schizophr Bull. 2004;30(4):767\u201379.","journal-title":"Schizophr Bull"},{"issue":"4","key":"157_CR235","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1007\/s00213-011-2247-y","volume":"216","author":"A Newman-Tancredi","year":"2011","unstructured":"Newman-Tancredi A, Kleven MS. Comparative pharmacology of antipsychotics possessing combined dopamine D2 and serotonin 5-HT1A receptor properties. Psychopharmacology (Berl). 2011;216(4):451\u201373.","journal-title":"Psychopharmacology (Berl)"},{"key":"157_CR236","doi-asserted-by":"crossref","unstructured":"Asenjo Lobos C, Komossa K, Rummel-Kluge C, et al. Clozapine versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev. 2010;(11):CD006633.","DOI":"10.1002\/14651858.CD006633.pub2"},{"issue":"3","key":"157_CR237","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s004060170049","volume":"251","author":"M Markianos","year":"2001","unstructured":"Markianos M, Hatzimanolis J, Lykouras L. Neuroendocrine responsivities of the pituitary dopamine system in male schizophrenic patients during treatment with clozapine, olanzapine, risperidone, sulpiride, or haloperidol. Eur Arch Psychiatry Clin Neurosci. 2001;251(3):141\u20136.","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"issue":"5","key":"157_CR238","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1007\/s00406-004-0505-2","volume":"254","author":"J Leon de","year":"2004","unstructured":"de Leon J, Diaz FJ, Josiassen RC, et al. Possible individual and gender differences in the small increases in plasma prolactin levels seen during clozapine treatment. Eur Arch Psychiatry Clin Neurosci. 2004;254(5):318\u201325.","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"issue":"6","key":"157_CR239","doi-asserted-by":"crossref","first-page":"761","DOI":"10.4088\/JCP.v66n0614","volume":"66","author":"K Melkersson","year":"2005","unstructured":"Melkersson K. Differences in prolactin elevation and related symptoms of atypical antipsychotics in schizophrenic patients. J Clin Psychiatry. 2005;66(6):761\u20137.","journal-title":"J Clin Psychiatry"},{"issue":"3","key":"157_CR240","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1002\/hup.924","volume":"23","author":"M Baggaley","year":"2008","unstructured":"Baggaley M. Sexual dysfunction in schizophrenia: focus on recent evidence. Hum Psychopharmacol. 2008;23(3):201\u20139.","journal-title":"Hum Psychopharmacol"},{"issue":"2","key":"157_CR241","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1176\/ajp.156.2.294","volume":"156","author":"AF Breier","year":"1999","unstructured":"Breier AF, Malhotra AK, Su TP, et al. Clozapine and risperidone in chronic schizophrenia: effects on symptoms, parkinsonian side effects, and neuroendocrine response. Am J Psychiatry. 1999;156(2):294\u20138.","journal-title":"Am J Psychiatry"},{"issue":"1","key":"157_CR242","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1176\/appi.ajp.159.1.133","volume":"159","author":"P Turrone","year":"2002","unstructured":"Turrone P, Kapur S, Seeman MV, et al. Elevation of prolactin levels by atypical antipsychotics. Am J Psychiatry. 2002;159(1):133\u20135.","journal-title":"Am J Psychiatry"},{"issue":"7","key":"157_CR243","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1177\/0269881107078281","volume":"21","author":"C Bushe","year":"2007","unstructured":"Bushe C, Shaw M. Prevalence of hyperprolactinaemia in a naturalistic cohort of schizophrenia and bipolar outpatients during treatment with typical and atypical antipsychotics. J Psychopharmacol. 2007;21(7):768\u201373.","journal-title":"J Psychopharmacol"},{"key":"157_CR244","volume-title":"Antipsychotic drugs and their side-effects","author":"JG Edwards","year":"1993","unstructured":"Edwards JG, Barnes TRE. The side-effects of antipsychotic drugs. II. Effects on other physiological systems. In: Barnes T, editor. Antipsychotic drugs and their side-effects. London: Academic Press, Harcourt Brace & Company, Publishers; 1993."},{"issue":"1","key":"157_CR245","first-page":"51","volume":"42","author":"RR Conley","year":"2005","unstructured":"Conley RR, Kelly DL. Second-generation antipsychotics for schizophrenia: a review of clinical pharmacology and medication-associated side effects. Isr J Psychiatry Relat Sci. 2005;42(1):51\u201360.","journal-title":"Isr J Psychiatry Relat Sci"},{"issue":"5","key":"157_CR246","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1097\/00004714-199710000-00010","volume":"17","author":"PV Tran","year":"1997","unstructured":"Tran PV, Hamilton SH, Kuntz AJ, et al. Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. J Clin Psychopharmacol. 1997;17(5):407\u201318.","journal-title":"J Clin Psychopharmacol"},{"issue":"11","key":"157_CR247","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.4088\/JCP.08m04446yel","volume":"70","author":"RC Smith","year":"2009","unstructured":"Smith RC, Lindenmayer JP, Davis JM, Kelly E, Viviano TF, Cornwell J, Hu Q, Khan A, Vaidhyanathaswamy S. Effects of olanzapine and risperidone on glucose metabolism and insulin sensitivity in chronic schizophrenic patients with long-term antipsychotic treatment: a randomized 5-month study. J Clin Psychiatry. 2009;70(11):1501\u201313.","journal-title":"J Clin Psychiatry"},{"issue":"1","key":"157_CR248","doi-asserted-by":"crossref","first-page":"16","DOI":"10.4088\/PCC.08m00668","volume":"11","author":"YL Chen","year":"2009","unstructured":"Chen YL, Cheng TS, Lung FW. Prolactin levels in olanzapine treatment correlate with positive symptoms of schizophrenia: results from an open-label, flexible-dose study. Prim Care Companion J Clin Psychiatry. 2009;11(1):16\u201320.","journal-title":"Prim Care Companion J Clin Psychiatry"},{"issue":"11","key":"157_CR249","doi-asserted-by":"crossref","first-page":"833","DOI":"10.4088\/JCP.v61n1105","volume":"61","author":"BJ Kinon","year":"2000","unstructured":"Kinon BJ, Basson BR, Gilmore JA, et al. Strategies for switching from conventional antipsychotic drugs or risperidone to olanzapine. J Clin Psychiatry. 2000;61(11):833\u201340.","journal-title":"J Clin Psychiatry"},{"issue":"10","key":"157_CR250","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.4088\/JCP.v64n1008","volume":"64","author":"JL Karagianis","year":"2003","unstructured":"Karagianis JL, Baksh A. High-dose olanzapine and prolactin levels. J Clin Psychiatry. 2003;64(10):1192\u20134.","journal-title":"J Clin Psychiatry"},{"issue":"2","key":"157_CR251","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/0893-133X(95)00069-P","volume":"14","author":"CM Beasley Jr","year":"1996","unstructured":"Beasley CM Jr, Tollefson G, Tran P, et al. Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial. Neuropsychopharmacology. 1996;14(2):111\u201323.","journal-title":"Neuropsychopharmacology"},{"issue":"2","key":"157_CR252","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S0924-977X(96)00392-6","volume":"7","author":"CM Beasley Jr","year":"1997","unstructured":"Beasley CM Jr, Hamilton SH, Crawford AM, et al. Olanzapine versus haloperidol: acute phase results of the international double-blind olanzapine trial. Eur Neuropsychopharmacol. 1997;7(2):125\u201337.","journal-title":"Eur Neuropsychopharmacol"},{"issue":"6","key":"157_CR253","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1002\/hup.1218","volume":"26","author":"Y Suzuki","year":"2011","unstructured":"Suzuki Y, Ono S, Sugai T, et al. Dose-dependent effects of olanzapine on QT intervals and plasma prolactin levels in Japanese patients with stable schizophrenia. Hum Psychopharmacol. 2011;26(6):440\u20133.","journal-title":"Hum Psychopharmacol"},{"key":"157_CR254","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/1471-244X-11-28","volume":"11","author":"AL Hill","year":"2011","unstructured":"Hill AL, Sun B, Karagianis JL, et al. Dose-associated changes in safety and efficacy parameters observed in a 24-week maintenance trial of olanzapine long-acting injection in patients with schizophrenia. BMC Psychiatry. 2011;11:28.","journal-title":"BMC Psychiatry"},{"issue":"3","key":"157_CR255","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1002\/hup.2308","volume":"28","author":"T Cabaleiro","year":"2013","unstructured":"Cabaleiro T, L\u00f3pez-Rodr\u00edguez R, Ochoa D, et al. Polymorphisms influencing olanzapine metabolism and adverse effects in healthy subjects. Hum Psychopharmacol. 2013;28(3):205\u201314.","journal-title":"Hum Psychopharmacol"},{"issue":"5","key":"157_CR256","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1097\/JCP.0b013e31822cfff2","volume":"31","author":"R L\u00f3pez-Rodr\u00edguez","year":"2011","unstructured":"L\u00f3pez-Rodr\u00edguez R, Rom\u00e1n M, Novalbos J, et al. DRD2 Taq1A polymorphism modulates prolactin secretion induced by atypical antipsychotics in healthy volunteers. J Clin Psychopharmacol. 2011;31(5):555\u201362.","journal-title":"J Clin Psychopharmacol"},{"issue":"10","key":"157_CR257","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.2165\/11204840-000000000-00000","volume":"70","author":"CM Chwieduk","year":"2010","unstructured":"Chwieduk CM, Keating GM. Paliperidone extended release: a review of its use in the management of schizophrenia. Drugs. 2010;70(10):1295\u2013317.","journal-title":"Drugs"},{"issue":"6","key":"157_CR258","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.20344\/amp.1415","volume":"24","author":"MM Carvalho","year":"2011","unstructured":"Carvalho MM, G\u00f3is C. Hyperprolactinemia in mentally ill patients. Acta Med Port. 2011;24(6):1005\u201312.","journal-title":"Acta Med Port"},{"issue":"1","key":"157_CR259","first-page":"5","volume":"47","author":"C Bellantuono","year":"2012","unstructured":"Bellantuono C, Santone G. Efficacy, tolerability and safety of paliperidone extended-release in the treatment of schizophrenia and schizoaffective disorder. Riv Psichiatr. 2012;47(1):5\u201320.","journal-title":"Riv Psichiatr"},{"issue":"6","key":"157_CR260","first-page":"869","volume":"3","author":"PG Janicak","year":"2007","unstructured":"Janicak PG, Winans EA. Paliperidone ER: a review of the clinical trial data. Neuropsychiatr Dis Treat. 2007;3(6):869\u201397.","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"1","key":"157_CR261","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s00213-013-3073-1","volume":"230","author":"S Hu","year":"2013","unstructured":"Hu S, Yao M, Peterson BS, et al. A randomized, 12-week study of the effects of extended-release paliperidone (paliperidone ER) and olanzapine on metabolic profile, weight, insulin resistance, and \u03b2-cell function in schizophrenic patients. Psychopharmacology (Berl). 2013;230(1):3\u201313.","journal-title":"Psychopharmacology (Berl)"},{"issue":"5","key":"157_CR262","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1097\/YIC.0b013e328356acad","volume":"27","author":"SW Kim","year":"2012","unstructured":"Kim SW, Chung YC, Lee YH, et al. Paliperidone ER versus risperidone for neurocognitive function in patients with schizophrenia: a randomized, open-label, controlled trial. Int Clin Psychopharmacol. 2012;27(5):267\u201374.","journal-title":"Int Clin Psychopharmacol"},{"issue":"1","key":"157_CR263","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1097\/YIC.0b013e32835ba832","volume":"28","author":"I Montalvo","year":"2013","unstructured":"Montalvo I, Ortega L, L\u00f3pez X, et al. Changes in prolactin levels and sexual function in young psychotic patients after switching from long-acting injectable risperidone to paliperidone palmitate. Int Clin Psychopharmacol. 2013;28(1):46\u20139.","journal-title":"Int Clin Psychopharmacol"},{"issue":"2","key":"157_CR264","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1111\/pcn.12026","volume":"67","author":"H Suzuki","year":"2013","unstructured":"Suzuki H, Gen K, Otomo M, et al. Study of the efficacy and safety of switching from risperidone to paliperidone in elderly patients with schizophrenia. Psychiatry Clin Neurosci. 2013;67(2):76\u201382.","journal-title":"Psychiatry Clin Neurosci"},{"issue":"10","key":"157_CR265","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1345\/aph.1R123","volume":"46","author":"TR Einarson","year":"2012","unstructured":"Einarson TR, Hemels ME, Nuamah I, et al. An analysis of potentially prolactin-related adverse events and abnormal prolactin values in randomized clinical trials with paliperidone palmitate. Ann Pharmacother. 2012;46(10):1322\u201330.","journal-title":"Ann Pharmacother"},{"key":"157_CR266","first-page":"375","volume":"8","author":"JK Sliwa","year":"2012","unstructured":"Sliwa JK, Bossie CA, Fu DJ, et al. Long-term tolerability of once-monthly injectable paliperidone palmitate in subjects with recently diagnosed schizophrenia. Neuropsychiatr Dis Treat. 2012;8:375\u201385.","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"1\u20132","key":"157_CR267","doi-asserted-by":"crossref","first-page":"e51","DOI":"10.1016\/j.jad.2010.06.030","volume":"136","author":"J Berwaerts","year":"2012","unstructured":"Berwaerts J, Xu H, Nuamah I, et al. Evaluation of the efficacy and safety of paliperidone extended-release in the treatment of acute mania: a randomized, double-blind, dose-response study. J Affect Disord. 2012;136(1\u20132):e51\u201360.","journal-title":"J Affect Disord"},{"key":"157_CR268","first-page":"1","volume":"22","author":"WW Fleischhacker","year":"2011","unstructured":"Fleischhacker WW, Gopal S, Lane R, et al. A randomized trial of paliperidone palmitate and risperidone long-acting injectable in schizophrenia. Int J Neuropsychopharmacol. 2011;22:1\u201312.","journal-title":"Int J Neuropsychopharmacol"},{"issue":"3","key":"157_CR269","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1097\/JCP.0b013e3181dd3103","volume":"30","author":"GJ Pandina","year":"2010","unstructured":"Pandina GJ, Lindenmayer JP, Lull J, et al. A randomized, placebo-controlled study to assess the efficacy and safety of 3 doses of paliperidone palmitate in adults with acutely exacerbated schizophrenia. J Clin Psychopharmacol. 2010;30(3):235\u201344.","journal-title":"J Clin Psychopharmacol"},{"issue":"1","key":"157_CR270","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.pnpbp.2010.11.008","volume":"35","author":"G Pandina","year":"2011","unstructured":"Pandina G, Lane R, Gopal S, et al. A double-blind study of paliperidone palmitate and risperidone long-acting injectable in adults with schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2011;35(1):218\u201326.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"157_CR271","doi-asserted-by":"crossref","first-page":"561","DOI":"10.2147\/NDT.S8505","volume":"6","author":"D Bishara","year":"2010","unstructured":"Bishara D. Once-monthly paliperidone injection for the treatment of schizophrenia. Neuropsychiatr Dis Treat. 2010;6:561\u201372.","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"5","key":"157_CR272","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1097\/YIC.0b013e32833948fa","volume":"25","author":"S Gopal","year":"2010","unstructured":"Gopal S, Hough DW, Xu H, et al. Efficacy and safety of paliperidone palmitate in adult patients with acutely symptomatic schizophrenia: a randomized, double-blind, placebo-controlled, dose-response study. Int Clin Psychopharmacol. 2010;25(5):247\u201356.","journal-title":"Int Clin Psychopharmacol"},{"issue":"6","key":"157_CR273","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1176\/appi.ajp.2009.08040613","volume":"166","author":"CM Canuso","year":"2009","unstructured":"Canuso CM, Dirks B, Carothers J, et al. Randomized, double-blind, placebo-controlled study of paliperidone extended-release and quetiapine in inpatients with recently exacerbated schizophrenia. Am J Psychiatry. 2009;166(6):691\u2013701.","journal-title":"Am J Psychiatry"},{"issue":"5","key":"157_CR274","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1097\/JCP.0b013e3181eeb600","volume":"30","author":"CM Canuso","year":"2010","unstructured":"Canuso CM, Schooler N, Carothers J, et al. Paliperidone extended-release in schizoaffective disorder: a randomized, controlled study comparing a flexible dose with placebo in patients treated with and without antidepressants and\/or mood stabilizers. J Clin Psychopharmacol. 2010;30(5):487\u201395.","journal-title":"J Clin Psychopharmacol"},{"issue":"1","key":"157_CR275","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1097\/JGP.0b013e31815a3e7a","volume":"16","author":"A Tzimos","year":"2008","unstructured":"Tzimos A, Samokhvalov V, Kramer M, et al. Safety and tolerability of oral paliperidone extended-release tablets in elderly patients with schizophrenia: a double-blind, placebo-controlled study with six-month open-label extension. Am J Geriatr Psychiatry. 2008;16(1):31\u201343.","journal-title":"Am J Geriatr Psychiatry"},{"issue":"1\u20133","key":"157_CR276","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.schres.2006.09.012","volume":"90","author":"J Kane","year":"2007","unstructured":"Kane J, Canas F, Kramer M, et al. Treatment of schizophrenia with paliperidone extended-release tablets: a 6-week placebo-controlled trial. Schizophr Res. 2007;90(1\u20133):147\u201361.","journal-title":"Schizophr Res"},{"issue":"1\u20133","key":"157_CR277","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.schres.2007.03.003","volume":"93","author":"M Davidson","year":"2007","unstructured":"Davidson M, Emsley R, Kramer M, et al. Efficacy, safety and early response of paliperidone extended-release tablets (paliperidone ER): results of a 6-week, randomized, placebo-controlled study. Schizophr Res. 2007;93(1\u20133):117\u201330.","journal-title":"Schizophr Res"},{"issue":"12","key":"157_CR278","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1016\/j.biopsych.2007.01.017","volume":"62","author":"SR Marder","year":"2007","unstructured":"Marder SR, Kramer M, Ford L, et al. Efficacy and safety of paliperidone extended-release tablets: results of a 6-week, randomized, placebo-controlled study. Biol Psychiatry. 2007;62(12):1363\u201370.","journal-title":"Biol Psychiatry"},{"issue":"6","key":"157_CR279","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1016\/j.pnpbp.2009.05.014","volume":"33","author":"D Hough","year":"2009","unstructured":"Hough D, Lindenmayer JP, Gopal S, et al. Safety and tolerability of deltoid and gluteal injections of paliperidone palmitate in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2009;33(6):1022\u201331.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"issue":"2\u20133","key":"157_CR280","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.schres.2009.10.026","volume":"116","author":"D Hough","year":"2010","unstructured":"Hough D, Gopal S, Vijapurkar U, et al. Paliperidone palmitate maintenance treatment in delaying the time-to-relapse in patients with schizophrenia: a randomized, double-blind, placebo-controlled study. Schizophr Res. 2010;116(2\u20133):107\u201317.","journal-title":"Schizophr Res"},{"issue":"5","key":"157_CR281","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1017\/S1461145709990988","volume":"13","author":"M Kramer","year":"2010","unstructured":"Kramer M, Litman R, Hough D, et al. Paliperidone palmitate, a potential long-acting treatment for patients with schizophrenia. Results of a randomized, double-blind, placebo-controlled efficacy and safety study. Int J Neuropsychopharmacol. 2010;13(5):635\u201347.","journal-title":"Int J Neuropsychopharmacol"},{"issue":"10","key":"157_CR282","doi-asserted-by":"crossref","first-page":"2072","DOI":"10.1038\/npp.2010.79","volume":"35","author":"HA Nasrallah","year":"2010","unstructured":"Nasrallah HA, Gopal S, Gassmann-Mayer C, et al. A controlled, evidence-based trial of paliperidone palmitate, a long-acting injectable antipsychotic, in schizophrenia. Neuropsychopharmacology. 2010;35(10):2072\u201382.","journal-title":"Neuropsychopharmacology"},{"issue":"7","key":"157_CR283","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1177\/0269881109106914","volume":"24","author":"J Berwaerts","year":"2010","unstructured":"Berwaerts J, Cleton A, Rossenu S, et al. A comparison of serum prolactin concentrations after administration of paliperidone extended-release and risperidone tablets in patients with schizophrenia. J Psychopharmacol. 2010;24(7):1011\u20138.","journal-title":"J Psychopharmacol"},{"issue":"2","key":"157_CR284","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/sj.ijir.3901260","volume":"17","author":"M Atmaca","year":"2005","unstructured":"Atmaca M, Kuloglu M, Tezcan E. A new atypical antipsychotic: quetiapine-induced sexual dysfunctions. Int J Impot Res. 2005;17(2):201\u20133.","journal-title":"Int J Impot Res"},{"issue":"4","key":"157_CR285","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/S0006-3223(97)00190-X","volume":"42","author":"LA Arvanitis","year":"1997","unstructured":"Arvanitis LA, Miller BG. Multiple fixed doses of \u201cSeroquel\u201d (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. The Seroquel Trial 13 Study Group. Biol Psychiatry. 1997;42(4):233\u201346.","journal-title":"Biol Psychiatry"},{"key":"157_CR286","doi-asserted-by":"crossref","unstructured":"Asmal L, Flegar SJ, Wang J, et al. Quetiapine versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev. 2013;(11):CD006625.","DOI":"10.1002\/14651858.CD006625.pub3"},{"issue":"6","key":"157_CR287","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1007\/s00406-005-0622-6","volume":"255","author":"M Riedel","year":"2005","unstructured":"Riedel M, M\u00fcller N, Strassnig M, et al. Quetiapine has equivalent efficacy and superior tolerability to risperidone in the treatment of schizophrenia with predominantly negative symptoms. Eur Arch Psychiatry Clin Neurosci. 2005;255(6):432\u20137.","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"issue":"2\u20133","key":"157_CR288","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.schres.2003.06.001","volume":"66","author":"PF Buckley","year":"2004","unstructured":"Buckley PF, Goldstein JM, Emsley RA. Efficacy and tolerability of quetiapine in poorly responsive, chronic schizophrenia. Schizophr Res. 2004;66(2\u20133):143\u201350.","journal-title":"Schizophr Res"},{"issue":"5","key":"157_CR289","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1080\/00926230490465082","volume":"30","author":"MJ Byerly","year":"2004","unstructured":"Byerly MJ, Lescouflair E, Weber MT, et al. An open-label trial of quetiapine for antipsychotic-induced sexual dysfunction. J Sex Marital Ther. 2004;30(5):325\u201332.","journal-title":"J Sex Marital Ther"},{"issue":"6","key":"157_CR290","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1001\/archpsyc.1997.01830180067009","volume":"54","author":"JG Small","year":"1997","unstructured":"Small JG, Hirsch SR, Arvanitis LA, et al. Quetiapine in patients with schizophrenia. A high- and low-dose double-blind comparison with placebo. Seroquel Study Group. Arch Gen Psychiatry. 1997;54(6):549\u201357.","journal-title":"Arch Gen Psychiatry"},{"issue":"2","key":"157_CR291","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1097\/00004714-199604000-00008","volume":"16","author":"RL Borison","year":"1996","unstructured":"Borison RL, Arvanitis LA, Miller BG. ICI 204,636, an atypical antipsychotic: efficacy and safety in a multicenter, placebo-controlled trial in patients with schizophrenia. U.S. SEROQUEL Study Group. J Clin Psychopharmacol. 1996;16(2):158\u201369.","journal-title":"J Clin Psychopharmacol"},{"issue":"5","key":"157_CR292","doi-asserted-by":"crossref","first-page":"696","DOI":"10.4088\/JCP.v65n0516","volume":"65","author":"R Emsley","year":"2004","unstructured":"Emsley R, Turner HJ, Schronen J, et al. A single-blind, randomized trial comparing quetiapine and haloperidol in the treatment of tardive dyskinesia. J Clin Psychiatry. 2004;65(5):696\u2013701.","journal-title":"J Clin Psychiatry"},{"issue":"1","key":"157_CR293","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1017\/S0033291799001476","volume":"30","author":"DL Copolov","year":"2000","unstructured":"Copolov DL, Link CGG, Kowalcyk B. A multicentre, double-blind, randomized comparison of quetiapine (ICI 204,636, \u2018Seroquel\u2019) and haloperidol in schizophrenia. Psychol Med. 2000;30(1):95\u2013105.","journal-title":"Psychol Med"},{"issue":"2","key":"157_CR294","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/s002130050603","volume":"137","author":"DJ King","year":"1998","unstructured":"King DJ, Link CG, Kowalcyk B. A comparison of bd and tid dose regimens of quetiapine (Seroquel) in the treatment of schizophrenia. Psychopharmacology (Berl). 1998;137(2):139\u201346.","journal-title":"Psychopharmacology (Berl)"},{"issue":"6","key":"157_CR295","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1001\/archpsyc.57.6.553","volume":"57","author":"S Kapur","year":"2000","unstructured":"Kapur S, Zipursky R, Jones C, et al. A positron emission tomography study of quetiapine in schizophrenia: a preliminary finding of an antipsychotic effect with only transiently high dopamine D2 receptor occupancy. Arch Gen Psychiatry. 2000;57(6):553\u20139.","journal-title":"Arch Gen Psychiatry"},{"issue":"12","key":"157_CR296","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1038\/npp.2010.111","volume":"35","author":"W Gaebel","year":"2010","unstructured":"Gaebel W, Schreiner A, Bergmans P, et al. Relapse prevention in schizophrenia and schizoaffective disorder with risperidone long-acting injectable vs quetiapine: results of a long-term, open-label, randomized clinical trial. Neuropsychopharmacology. 2010;35(12):2367\u201377.","journal-title":"Neuropsychopharmacology"},{"issue":"5","key":"157_CR297","first-page":"617","volume":"81","author":"J Muench","year":"2010","unstructured":"Muench J, Hamer AM. Adverse effects of antipsychotic medications. Am Fam Physician. 2010;81(5):617\u201322.","journal-title":"Am Fam Physician"},{"key":"157_CR298","doi-asserted-by":"crossref","unstructured":"Komossa K, Rummel-Kluge C, Schwarz S, et al. Risperidone versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev. 2011;(1):CD006626.","DOI":"10.1002\/14651858.CD006626.pub2"},{"issue":"9896","key":"157_CR299","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/S0140-6736(13)60733-3","volume":"382","author":"S Leucht","year":"2013","unstructured":"Leucht S, Cipriani A, Spineli L, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet. 2013;382(9896):951\u201362.","journal-title":"Lancet"},{"issue":"2","key":"157_CR300","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.pnpbp.2003.10.006","volume":"28","author":"YC Yen","year":"2004","unstructured":"Yen YC, Lung FW, Chong MY. Adverse effects of risperidone and haloperidol treatment in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2004;28(2):285\u201390.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"157_CR301","doi-asserted-by":"crossref","first-page":"77","DOI":"10.2147\/NDT.S16664","volume":"7","author":"H Zhang","year":"2011","unstructured":"Zhang H, Li H, Shu L, et al. Double-blind comparison of ziprasidone and risperidone in the treatment of Chinese patients with acute exacerbation of schizophrenia. Neuropsychiatr Dis Treat. 2011;7:77\u201385.","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"4","key":"157_CR302","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1080\/00926230600666378","volume":"32","author":"H Knegtering","year":"2006","unstructured":"Knegtering H, Boks M, Blijd C, et al. A randomized open-label comparison of the impact of olanzapine versus risperidone on sexual functioning. J Sex Marital Ther. 2006;32(4):315\u201326.","journal-title":"J Sex Marital Ther"},{"issue":"5","key":"157_CR303","doi-asserted-by":"crossref","first-page":"408","DOI":"10.4088\/JCP.v63n0506","volume":"63","author":"KS Kim","year":"2002","unstructured":"Kim KS, Pae CU, Chae JH, et al. Effects of olanzapine on prolactin levels of female patients with schizophrenia treated with risperidone. J Clin Psychiatry. 2002;63(5):408\u201313.","journal-title":"J Clin Psychiatry"},{"issue":"6","key":"157_CR304","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1089\/cap.2005.15.893","volume":"15","author":"JR Stevens","year":"2005","unstructured":"Stevens JR, Kymissis PI, Baker AJ. Elevated prolactin levels in male youths treated with risperidone and quetiapine. J Child Adolesc Psychopharmacol. 2005;15(6):893\u2013900.","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"6","key":"157_CR305","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1192\/bjp.166.6.712","volume":"166","author":"J Peuskens","year":"1995","unstructured":"Peuskens J. Risperidone in the treatment of patients with chronic schizophrenia: a multi-national, multi-centre, double-blind, parallel-group study versus haloperidol. Risperidone Study Group. Br J Psychiatry. 1995;166(6):712\u201326.","journal-title":"Br J Psychiatry"},{"issue":"1","key":"157_CR306","first-page":"143","volume":"36","author":"MT Compton","year":"2002","unstructured":"Compton MT, Miller AH. Antipsychotic-induced hyperprolactinemia and sexual dysfunction. Psychopharmacol Bull. 2002;36(1):143\u201364.","journal-title":"Psychopharmacol Bull"},{"issue":"6","key":"157_CR307","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1089\/cap.2008.0144","volume":"19","author":"M Haas","year":"2009","unstructured":"Haas M, Unis AS, Armenteros J, et al. A 6-week, randomized, double-blind, placebo-controlled study of the efficacy and safety of risperidone in adolescents with schizophrenia. J Child Adolesc Psychopharmacol. 2009;19(6):611\u201321.","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"157_CR308","unstructured":"Canuso CM, Bossie CA, Lasser RA, et al. Reduced serum prolactin levels after treatmetn with long-acting risperidone. Poster at 156th APA congress, San Francisco; 2003."},{"issue":"1","key":"157_CR309","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.euroneuro.2004.07.003","volume":"15","author":"P Chue","year":"2005","unstructured":"Chue P, Eerdekens M, Augustyns I, et al. Comparative efficacy and safety of long-acting risperidone and risperidone oral tablets. Eur Neuropsychopharmacol. 2005;15(1):111\u20137.","journal-title":"Eur Neuropsychopharmacol"},{"issue":"6","key":"157_CR310","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1097\/JCP.0b013e31818d7ca2","volume":"28","author":"PW Peng","year":"2008","unstructured":"Peng PW, Huang MC, Tsai CJ, et al. The disparity of pharmacokinetics and prolactin study for risperidone long-acting injection. J Clin Psychopharmacol. 2008;28(6):726\u20137.","journal-title":"J Clin Psychopharmacol"},{"issue":"3","key":"157_CR311","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1097\/01.jcp.0000270090.55156.7a","volume":"27","author":"YM Bai","year":"2007","unstructured":"Bai YM, Chen TT, Lin WK, et al. Pharmacokinetics study for hyperprolactinemia among schizophrenics switched from risperidone to risperidone long-acting injection. J Clin Psychopharmacol. 2007;27(3):306\u20138.","journal-title":"J Clin Psychopharmacol"},{"issue":"3","key":"157_CR312","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1002\/hup.1104","volume":"25","author":"S Verma","year":"2010","unstructured":"Verma S, Subramaniam M, Abdin E, et al. Safety and efficacy of long-acting injectable risperidone in patients with schizophrenia spectrum disorders: a 6-month open-label trial in Asian patients. Hum Psychopharmacol. 2010;25(3):230\u20135.","journal-title":"Hum Psychopharmacol"},{"issue":"11","key":"157_CR313","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1586\/ern.10.143","volume":"10","author":"WV Bobo","year":"2010","unstructured":"Bobo WV, Shelton RC. Risperidone long-acting injectable (Risperdal Consta\u00ae) for maintenance treatment in patients with bipolar disorder. Expert Rev Neurother. 2010;10(11):1637\u201358.","journal-title":"Expert Rev Neurother"},{"key":"157_CR314","doi-asserted-by":"crossref","first-page":"391","DOI":"10.2147\/NDT.S20589","volume":"7","author":"MR Louz\u00e3","year":"2011","unstructured":"Louz\u00e3 MR, Elkis H, Ruschel S, et al. Long-acting injectable risperidone in partially adherent and nonadherent patients with schizophrenia. Neuropsychiatr Dis Treat. 2011;7:391\u20138.","journal-title":"Neuropsychiatr Dis Treat"},{"key":"157_CR315","doi-asserted-by":"crossref","unstructured":"Szerman N, Basurte-Villamor I, Montes JM, et al.. Prolactin levels and side effects of long-acting risperidone injection and oral treatments in psychotic disorders. Poster at 20th ECNP congress, Vienna; 2007.","DOI":"10.1016\/S0924-977X(07)70670-3"},{"issue":"5","key":"157_CR316","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1176\/appi.ajp.162.5.1010","volume":"162","author":"R Knegtering","year":"2005","unstructured":"Knegtering R, Baselmans P, Castelein S, et al. Predominant role of the 9-hydroxy metabolite of risperidone in elevating blood prolactin levels. Am J Psychiatry. 2005;162(5):1010\u20132.","journal-title":"Am J Psychiatry"},{"issue":"8","key":"157_CR317","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1002\/hup.811","volume":"21","author":"KI Melkersson","year":"2006","unstructured":"Melkersson KI. Prolactin elevation of the antipsychotic risperidone is predominantly related to its 9-hydroxy metabolite. Hum Psychopharmacol. 2006;21(8):529\u201332.","journal-title":"Hum Psychopharmacol"},{"key":"157_CR318","first-page":"187","volume":"4","author":"MR Muscatello","year":"2010","unstructured":"Muscatello MR, Bruno A, Pandolfo G, et al. Emerging treatments in the management of schizophrenia - focus on sertindole. Drug Des Dev Ther. 2010;4:187\u2013201.","journal-title":"Drug Des Dev Ther"},{"issue":"1\u20132","key":"157_CR319","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1007\/BF02245618","volume":"124","author":"DP Kammen van","year":"1996","unstructured":"van Kammen DP, McEvoy JP, Targum SD, et al. A randomized, controlled,\u00a0dose ranging trial of sertindole in patients with schizophrenia. Psychopharmacology (Berl). 1996;124(1\u20132):168\u201375.","journal-title":"Psychopharmacology (Berl)"},{"issue":"4","key":"157_CR320","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1097\/YIC.0b013e328354dcda","volume":"27","author":"AS Hale","year":"2012","unstructured":"Hale AS, Azorin JM, Lemming OM, et al. Sertindole in the long-term treatment of schizophrenia. Int Clin Psychopharmacol. 2012;27(4):231\u20137.","journal-title":"Int Clin Psychopharmacol"},{"issue":"3","key":"157_CR321","doi-asserted-by":"crossref","first-page":"233","DOI":"10.2165\/00023210-200620030-00005","volume":"20","author":"D Murdoch","year":"2006","unstructured":"Murdoch D, Keating GM. Sertindole: a review of its use in schizophrenia. CNS Drugs. 2006;20(3):233\u201355.","journal-title":"CNS Drugs"},{"issue":"5","key":"157_CR322","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1517\/17425255.4.5.629","volume":"4","author":"E Spina","year":"2008","unstructured":"Spina E, Zoccali R. Sertindole: pharmacological and clinical profile and role in the treatment of schizophrenia. Expert Opin Drug Metab Toxicol. 2008;4(5):629\u201338.","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"3","key":"157_CR323","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1517\/14740338.2011.560114","volume":"10","author":"L Citrome","year":"2011","unstructured":"Citrome L. Drug safety evaluation of ziprasidone. Expert Opin Drug Saf. 2011;10(3):437\u201348.","journal-title":"Expert Opin Drug Saf"},{"issue":"10","key":"157_CR324","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1176\/appi.ajp.161.10.1925","volume":"161","author":"SI Lusskin","year":"2004","unstructured":"Lusskin SI, Cancro R, Chuang L, et al. Prolactin elevation with ziprasidone. Am J Psychiatry. 2004;161(10):1925.","journal-title":"Am J Psychiatry"},{"issue":"9","key":"157_CR325","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.4088\/JCP.v65n0918f","volume":"65","author":"I Anghelescu","year":"2004","unstructured":"Anghelescu I, Wolf J. Successful switch to aripiprazole after induction of hyperprolactinemia by ziprasidone: a case report. J Clin Psychiatry. 2004;65(9):1286\u20137.","journal-title":"J Clin Psychiatry"},{"issue":"12","key":"157_CR326","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/j.clinthera.2011.10.027","volume":"33","author":"E Stip","year":"2011","unstructured":"Stip E, Zhornitsky S, Moteshafi H, et al. Ziprasidone for psychotic disorders: a meta-analysis and systematic review of the relationship between pharmacokinetics, pharmacodynamics, and clinical profile. Clin Ther. 2011;33(12):1853\u201367.","journal-title":"Clin Ther"},{"issue":"1\u20133","key":"157_CR327","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.schres.2009.02.017","volume":"110","author":"E Sacchetti","year":"2009","unstructured":"Sacchetti E, Galluzzo A, Valsecchi P, et al. Ziprasidone vs clozapine in schizophrenia patients refractory to multiple antipsychotic treatments: the MOZART study. Schizophr Res. 2009;110(1\u20133):80\u20139.","journal-title":"Schizophr Res"},{"issue":"1","key":"157_CR328","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1177\/070674370905400108","volume":"54","author":"DE Addington","year":"2009","unstructured":"Addington DE, Labelle A, Kulkarni J, et al. A comparison of ziprasidone and risperidone in the long-term treatment of schizophrenia: a 44-week, double-blind, continuation study. Can J Psychiatry. 2009;54(1):46\u201354.","journal-title":"Can J Psychiatry"},{"issue":"5","key":"157_CR329","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1097\/00004850-200209000-00001","volume":"17","author":"M Arato","year":"2002","unstructured":"Arato M, O\u2019Connor R, Meltzer HY, et al. A 1-year, double-blind, placebo-controlled trial of ziprasidone 40, 80 and 160\u00a0mg\/day in chronic schizophrenia: the Ziprasidone Extended Use in Schizophrenia (ZEUS) study. Int Clin Psychopharmacol. 2002;17(5):207\u201315.","journal-title":"Int Clin Psychopharmacol"},{"issue":"3","key":"157_CR330","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1097\/WNF.0b013e3181d52b85","volume":"33","author":"SW Kim","year":"2010","unstructured":"Kim SW, Shin IS, Kim JM, et al. Effectiveness of switching from aripiprazole to ziprasidone in patients with schizophrenia. Clin Neuropharmacol. 2010;33(3):121\u20135.","journal-title":"Clin Neuropharmacol"},{"issue":"1","key":"157_CR331","first-page":"7","volume":"22","author":"XL Wu","year":"2012","unstructured":"Wu XL, Wang JH, Hu SH, et al. Serum prolactin levels and the acute-phase efficacy in drug-na\u00efve schizophrenia treated with ziprasidone and olanzapine (translated version). East Asian Arch Psychiatry. 2012;22(1):7\u201311.","journal-title":"East Asian Arch Psychiatry"},{"issue":"1","key":"157_CR332","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s00213-013-3012-1","volume":"228","author":"T Suzuki","year":"2013","unstructured":"Suzuki T, Graff-Guerrero A, Uchida H, et al. Dopamine D2\/3 occupancy of ziprasidone across a day: a within-subject PET study. Psychopharmacology (Berl). 2013;228(1):43\u201351.","journal-title":"Psychopharmacology (Berl)"},{"issue":"3","key":"157_CR333","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1177\/0269881108089593","volume":"23","author":"M Zink","year":"2009","unstructured":"Zink M, Kuwilsky A, Krumm B, et al. Efficacy and tolerability of ziprasidone versus risperidone as augmentation in patients partially responsive to clozapine: a randomised controlled clinical trial. J Psychopharmacol. 2009;23(3):305\u201314.","journal-title":"J Psychopharmacol"},{"issue":"4","key":"157_CR334","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1089\/cap.2008.0120","volume":"19","author":"Y Roke","year":"2009","unstructured":"Roke Y, van Harten PN, Boot AM, et al. Antipsychotic medication in children and adolescents: a descriptive review of the effects on prolactin level and associated side effects. J Child Adolesc Psychopharmacol. 2009;19(4):403\u201314.","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"2","key":"157_CR335","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1136\/ebmh.13.2.54","volume":"13","author":"C Correll","year":"2010","unstructured":"Correll C, Kishimoto T, Carlson H. Review: most antipsychotic drugs more than double the prolactin levels in children and adolescents. Evid Based Ment Health. 2010;13(2):54.","journal-title":"Evid Based Ment Health"},{"issue":"8","key":"157_CR336","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/j.euroneuro.2010.07.002","volume":"21","author":"D Fraguas","year":"2011","unstructured":"Fraguas D, Correll CU, Merch\u00e1n-Naranjo J, et al. Efficacy and safety of second-generation antipsychotics in children and adolescents with psychotic and bipolar spectrum disorders: comprehensive review of prospective head-to-head and placebo-controlled comparisons. Eur Neuropsychopharmacol. 2011;21(8):621\u20136.","journal-title":"Eur Neuropsychopharmacol"},{"issue":"2","key":"157_CR337","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/s40272-013-0016-6","volume":"15","author":"NB Almandil","year":"2013","unstructured":"Almandil NB, Liu Y, Murray ML, et al. Weight gain and other metabolic adverse effects associated with atypical antipsychotic treatment of children and adolescents: a systematic review and meta-analysis. Paediatr Drugs. 2013;15(2):139\u201350.","journal-title":"Paediatr Drugs"},{"issue":"8","key":"157_CR338","doi-asserted-by":"crossref","first-page":"651","DOI":"10.2165\/11592020-000000000-00000","volume":"34","author":"T Pringsheim","year":"2011","unstructured":"Pringsheim T, Lam D, Ching H, et al. Metabolic and neurological complications of second-generation antipsychotic use in children: a systematic review and meta-analysis of randomized controlled trials. Drug Saf. 2011;34(8):651\u201368.","journal-title":"Drug Saf"},{"issue":"Suppl","key":"157_CR339","doi-asserted-by":"crossref","first-page":"S15","DOI":"10.1016\/j.jad.2012.02.031","volume":"138","author":"T Doey","year":"2012","unstructured":"Doey T. Aripiprazole in pediatric psychosis and bipolar disorder: a clinical review. J Affect Disord. 2012;138(Suppl):S15\u201321.","journal-title":"J Affect Disord"},{"issue":"4","key":"157_CR340","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1089\/cap.2012.0062","volume":"23","author":"DJ Safer","year":"2013","unstructured":"Safer DJ, Calarge CA, Safer AM. Prolactin serum concentrations during aripiprazole treatment in youth. J Child Adolesc Psychopharmacol. 2013;23(4):282\u20139.","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"8","key":"157_CR341","doi-asserted-by":"crossref","first-page":"e772","DOI":"10.4088\/JCP.12m08189","volume":"74","author":"HK Yoo","year":"2013","unstructured":"Yoo HK, Joung YS, Lee JS, et al. A multicenter, randomized, double-blind, placebo-controlled study of aripiprazole in children and adolescents with Tourette\u2019s disorder. J Clin Psychiatry. 2013;74(8):e772\u201380.","journal-title":"J Clin Psychiatry"},{"key":"157_CR342","author":"SS Datta","year":"2013","unstructured":"Datta SS, Kumar A, Wright SD, et al. Evidence base for using atypical antipsychotics for psychosis in adolescents. Schizophr Bull. 2013;. doi: 10.1093\/schbul\/sbt196 .","journal-title":"Schizophr Bull"},{"key":"157_CR343","doi-asserted-by":"crossref","unstructured":"Kumar A, Datta SS, Wright SD,et al. Atypical antipsychotics for psychosis in adolescents. Cochrane Database Syst Rev 2013;(10):CD009582. doi: 10.1002\/14651858.CD009582.pub2 .","DOI":"10.1002\/14651858.CD009582.pub2"},{"issue":"1","key":"157_CR344","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/1753-2000-5-10","volume":"5","author":"ES Ercan","year":"2011","unstructured":"Ercan ES, Basay BK, Basay O, et al. Risperidone in the treatment of conduct disorder in preschool children without intellectual disability. Child Adolesc Psychiatry Ment Health. 2011;5(1):10.","journal-title":"Child Adolesc Psychiatry Ment Health"},{"issue":"9","key":"157_CR345","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1016\/j.jaac.2011.06.009","volume":"50","author":"J Hagman","year":"2011","unstructured":"Hagman J, Gralla J, Sigel E, et al. A double-blind, placebo-controlled study of risperidone for the treatment of adolescents and young adults with anorexia nervosa: a pilot study. J Am Acad Child Adolesc Psychiatry. 2011;50(9):915\u201324.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"2","key":"157_CR346","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1192\/bjp.bp.107.046177","volume":"194","author":"M Haas","year":"2009","unstructured":"Haas M, Eerdekens M, Kushner S, et al. Efficacy, safety and tolerability of two dosing regimens in adolescent schizophrenia: double-blind study. Br J Psychiatry. 2009;194(2):158\u201364.","journal-title":"Br J Psychiatry"},{"key":"157_CR347","unstructured":"Highlights of prescribing information. Risperdal. http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2010\/020272S-055S-058S-061S-062lbl.pdf . Revised Aug 2010. Accessed 14 Jan 2014."},{"key":"157_CR348","unstructured":"http:\/\/injurylawyer-news.com\/risperdal\/gynecomastia\/ . Accessed 14 Jan 2014."},{"key":"157_CR349","unstructured":"http:\/\/westrikeback.com\/practice-areas\/dangerous-defective-drugs\/risperdal\/ . Accessed 14 Jan 2014."},{"issue":"5","key":"157_CR350","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1517\/14740338.2012.712109","volume":"11","author":"F Deepinder","year":"2012","unstructured":"Deepinder F, Braunstein GD. Drug-induced gynecomastia: an evidence-based review. Expert Opin Drug Saf. 2012;11(5):779\u201395.","journal-title":"Expert Opin Drug Saf"},{"issue":"4","key":"157_CR351","first-page":"220","volume":"17","author":"D Elbe","year":"2008","unstructured":"Elbe D, Carandang CG. Focus on ziprasidone: a review of its use in child and adolescent psychiatry. J Can Acad Child Adolesc Psychiatry. 2008;17(4):220\u20139.","journal-title":"J Can Acad Child Adolesc Psychiatry"},{"issue":"2","key":"157_CR352","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1038\/nrendo.2011.156","volume":"8","author":"M Hert De","year":"2011","unstructured":"De Hert M, Detraux J, van Winkel R, et al. Metabolic and cardiovascular adverse effects associated with antipsychotic drugs. Nat Rev Endocrinol. 2011;8(2):114\u201326.","journal-title":"Nat Rev Endocrinol"},{"issue":"5","key":"157_CR353","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1097\/MED.0b013e32833de61c","volume":"17","author":"P Pramyothin","year":"2010","unstructured":"Pramyothin P, Khaodhiar L. Metabolic syndrome with the atypical antipsychotics. Curr Opin Endocrinol Diabetes Obes. 2010;17(5):460\u20136.","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"issue":"6","key":"157_CR354","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1017\/S1461145712001277","volume":"16","author":"JP Zhang","year":"2013","unstructured":"Zhang JP, Gallego JA, Robinson DG, et al. Efficacy and safety of individual second-generation vs. first-generation antipsychotics in first-episode psychosis: a systematic review and meta-analysis. Int J Neuropsychopharmacol. 2013;16(6):1205\u201318.","journal-title":"Int J Neuropsychopharmacol"},{"issue":"4","key":"157_CR355","first-page":"17","volume":"9","author":"A Shrivastava","year":"2012","unstructured":"Shrivastava A, Johnston M, Bureau Y, et al. Baseline serum prolactin in drug-naive, first-episode schizophrenia and outcome at five years: is it a predictive factor? Innov Clin Neurosci. 2012;9(4):17\u201321.","journal-title":"Innov Clin Neurosci"},{"issue":"2","key":"157_CR356","first-page":"141","volume":"32","author":"M Bicikova","year":"2011","unstructured":"Bicikova M, Hampl R, Hill M, et al. Neuro- and immunomodulatory steroids and other biochemical markers in drug-naive schizophrenia patients and the effect of treatment with atypical antipsychotics. Neuro Endocrinol Lett. 2011;32(2):141\u20137.","journal-title":"Neuro Endocrinol Lett"},{"issue":"6","key":"157_CR357","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1016\/j.pnpbp.2006.03.041","volume":"30","author":"H Takahashi","year":"2006","unstructured":"Takahashi H, Yoshida K, Ishigooka J, et al. Switching to risperidone after unsuccessful treatment of olanzapine in the first-episode schizophrenia: an open trial. Prog Neuropsychopharmacol Biol Psychiatry. 2006;30(6):1067\u201372.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"issue":"11","key":"157_CR358","doi-asserted-by":"crossref","first-page":"992","DOI":"10.4088\/JCP.v63n1106","volume":"63","author":"S Tauscher-Wisniewski","year":"2002","unstructured":"Tauscher-Wisniewski S, Kapur S, Tauscher J, et al. Quetiapine: an effective antipsychotic in first-episode schizophrenia despite only transiently high dopamine-2 receptor blockade. J Clin Psychiatry. 2002;63(11):992\u20137.","journal-title":"J Clin Psychiatry"},{"issue":"4","key":"157_CR359","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1097\/YIC.0b013e3283528d22","volume":"27","author":"T Zhao","year":"2012","unstructured":"Zhao T, Park TW, Yang JC, et al. Efficacy and safety of ziprasidone in the treatment of\u00a0first-episode psychosis: an 8-week, open-label, multicenter trial. Int Clin Psychopharmacol. 2012;27(4):184\u201390.","journal-title":"Int Clin Psychopharmacol"},{"issue":"3","key":"157_CR360","doi-asserted-by":"crossref","first-page":"122","DOI":"10.3371\/CSRP.6.3.4","volume":"6","author":"N Miyake","year":"2012","unstructured":"Miyake N, Miyamoto S, Jarskog LF. New serotonin\/dopamine antagonists for the treatment of schizophrenia: are we making real progress? Clin Schizophr Relat Psychoses. 2012;6(3):122\u201333.","journal-title":"Clin Schizophr Relat Psychoses"},{"issue":"1","key":"157_CR361","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1586\/ecp.12.70","volume":"6","author":"WV Bobo","year":"2013","unstructured":"Bobo WV. Asenapine, iloperidone and lurasidone: critical appraisal of the most recently approved pharmacotherapies for schizophrenia in adults. Expert Rev Clin Pharmacol. 2013;6(1):61\u201391.","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"1","key":"157_CR362","doi-asserted-by":"crossref","first-page":"34","DOI":"10.3371\/CSRP.6.1.5","volume":"6","author":"PJ Weiden","year":"2012","unstructured":"Weiden PJ. Iloperidone for the treatment of schizophrenia: an updated clinical review. Clin Schizophr Relat Psychoses. 2012;6(1):34\u201344.","journal-title":"Clin Schizophr Relat Psychoses"},{"issue":"4","key":"157_CR363","doi-asserted-by":"crossref","first-page":"217","DOI":"10.3371\/CSRP.5.4.6","volume":"5","author":"RS McIntyre","year":"2012","unstructured":"McIntyre RS, Wong R. Asenapine: a synthesis of efficacy data in bipolar mania and schizophrenia. Clin Schizophr Relat Psychoses. 2012;5(4):217\u201320.","journal-title":"Clin Schizophr Relat Psychoses"},{"issue":"6","key":"157_CR364","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1111\/j.1755-5949.2010.00200.x","volume":"17","author":"RS McIntyre","year":"2011","unstructured":"McIntyre RS. Asenapine: a review of acute and extension phase data in bipolar disorder. CNS Neurosci Ther. 2011;17(6):645\u20138.","journal-title":"CNS Neurosci Ther"},{"key":"157_CR365","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1186\/1471-244X-11-101","volume":"11","author":"A Szegedi","year":"2011","unstructured":"Szegedi A, Zhao J, van Willigenburg A, et al. Effects of asenapine on depressive symptoms in patients with bipolar I disorder experiencing acute manic or mixed episodes: a post hoc analysis of two 3-week clinical trials. BMC Psychiatry. 2011;11:101.","journal-title":"BMC Psychiatry"},{"issue":"12","key":"157_CR366","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.4088\/JCP.11r07596","volume":"73","author":"A Szegedi","year":"2012","unstructured":"Szegedi A, Verweij P, van Duijnhoven W, et al. Meta-analyses of the efficacy of asenapine for acute schizophrenia: comparisons with placebo and other antipsychotics. J Clin Psychiatry. 2012;73(12):1533\u201340.","journal-title":"J Clin Psychiatry"},{"key":"157_CR367","first-page":"247","volume":"8","author":"P Cazorla","year":"2012","unstructured":"Cazorla P, Mackle M, Zhao J, et al. Safety and tolerability of switching to asenapine from other antipsychotic agents: pooled results from two randomized multicenter trials in stable patients with persistent negative symptoms in schizophrenia. Neuropsychiatr Dis Treat. 2012;8:247\u201357.","journal-title":"Neuropsychiatr Dis Treat"},{"key":"157_CR368","doi-asserted-by":"crossref","first-page":"259","DOI":"10.2147\/NDT.S17259","volume":"7","author":"M Pompili","year":"2011","unstructured":"Pompili M, Venturini P, Innamorati M, et al. The role of asenapine in the treatment of manic or mixed states associated with bipolar I disorder. Neuropsychiatr Dis Treat. 2011;7:259\u201365.","journal-title":"Neuropsychiatr Dis Treat"},{"key":"157_CR369","first-page":"325","volume":"7","author":"L Citrome","year":"2011","unstructured":"Citrome L. Role of sublingual asenapine in treatment of schizophrenia. Neuropsychiatr Dis Treat. 2011;7:325\u201339.","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"11","key":"157_CR370","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1517\/14656566.2011.626767","volume":"13","author":"L Citrome","year":"2012","unstructured":"Citrome L, Nasrallah HA. On-label on the table: what the package insert informs us about the tolerability profile of oral atypical antipsychotics, and what it does not. Expert Opin Pharmacother. 2012;13(11):1599\u2013613.","journal-title":"Expert Opin Pharmacother"},{"key":"157_CR371","doi-asserted-by":"crossref","first-page":"333","DOI":"10.2147\/PPA.S10968","volume":"5","author":"JM Gonzalez","year":"2011","unstructured":"Gonzalez JM, Thompson PM, Moore TA. Review of the safety, efficacy, and side effect profile of asenapine in the treatment of bipolar 1 disorder. Patient Prefer Adherence. 2011;5:333\u201341.","journal-title":"Patient Prefer Adherence"},{"issue":"Suppl 1","key":"157_CR372","doi-asserted-by":"crossref","first-page":"14","DOI":"10.4088\/JCP.10075su1.03","volume":"72","author":"SG Potkin","year":"2011","unstructured":"Potkin SG. Asenapine: a clinical overview. J Clin Psychiatry. 2011;72(Suppl 1):14\u20138.","journal-title":"J Clin Psychiatry"},{"issue":"3","key":"157_CR373","doi-asserted-by":"crossref","first-page":"251","DOI":"10.2165\/11206700-000000000-00000","volume":"25","author":"CM Chwieduk","year":"2011","unstructured":"Chwieduk CM, Scott LJ. Asenapine: a review of its use in the management of mania in adults with bipolar I disorder. CNS Drugs. 2011;25(3):251\u201367.","journal-title":"CNS Drugs"},{"issue":"5","key":"157_CR374","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1586\/ern.10.49","volume":"10","author":"RS McIntyre","year":"2010","unstructured":"McIntyre RS. Pharmacology and efficacy of asenapine for manic and mixed states in adults with bipolar disorder. Expert Rev Neurother. 2010;10(5):645\u20139.","journal-title":"Expert Rev Neurother"},{"key":"157_CR375","first-page":"483","volume":"5","author":"D Bishara","year":"2009","unstructured":"Bishara D, Taylor D. Asenapine monotherapy in the acute treatment of both schizophrenia and bipolar I disorder. Neuropsychiatr Dis Treat. 2009;5:483\u201390.","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"2","key":"157_CR376","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1097\/JCP.0b013e3181d35d6b","volume":"30","author":"JM Kane","year":"2010","unstructured":"Kane JM, Cohen M, Zhao J, et al. Efficacy and safety of asenapine in a placebo- and haloperidol-controlled trial in patients with acute exacerbation of schizophrenia. J Clin Psychopharmacol. 2010;30(2):106\u201315.","journal-title":"J Clin Psychopharmacol"},{"issue":"Suppl 1","key":"157_CR377","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.schres.2007.12.104","volume":"98","author":"R McIntyre","year":"2008","unstructured":"McIntyre R, Alphs L, Cohen M, et al. Long-term double-blind extension studies of asenapine vs. olanzapine in patients with bipolar mania. Schizophr Res. 2008;98(Suppl 1):48\u20139.","journal-title":"Schizophr Res"},{"issue":"Suppl 1","key":"157_CR378","doi-asserted-by":"crossref","first-page":"S91","DOI":"10.1016\/j.jad.2007.12.082","volume":"107","author":"R McIntyre","year":"2008","unstructured":"McIntyre R, Alphs L, Cohen M, et al. Long-term double-blind extension studies of asenapine vs olanzapine in patients with bipolar mania. J Affect Disord. 2008;107(Suppl 1):S91\u20132.","journal-title":"J Affect Disord"},{"issue":"9","key":"157_CR379","doi-asserted-by":"crossref","first-page":"781","DOI":"10.2165\/11200860-000000000-00000","volume":"23","author":"J Weber","year":"2009","unstructured":"Weber J, McCormack PL. Asenapine. CNS Drugs. 2009;23(9):781\u201392.","journal-title":"CNS Drugs"},{"issue":"10","key":"157_CR380","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.4088\/JCP.v68n1004","volume":"68","author":"SG Potkin","year":"2007","unstructured":"Potkin SG, Cohen M, Panagides J. Efficacy and tolerability of asenapine in acute schizophrenia: a placebo- and risperidone-controlled trial. J Clin Psychiatry. 2007;68(10):1492\u2013500.","journal-title":"J Clin Psychiatry"},{"issue":"3","key":"157_CR381","doi-asserted-by":"crossref","first-page":"349","DOI":"10.4088\/JCP.10m06306","volume":"72","author":"JM Kane","year":"2011","unstructured":"Kane JM, Mackle M, Snow-Adami L, et al. A randomized placebo-controlled trial of asenapine for the prevention of relapse of schizophrenia after long-term treatment. J Clin Psychiatry. 2011;72(3):349\u201355.","journal-title":"J Clin Psychiatry"},{"issue":"3","key":"157_CR382","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.jad.2010.04.005","volume":"126","author":"RS McIntyre","year":"2010","unstructured":"McIntyre RS, Cohen M, Zhao J, et al. Asenapine for long-term treatment of bipolar disorder: a double-blind 40-week extension study. J Affect Disord. 2010;126(3):358\u201365.","journal-title":"J Affect Disord"},{"issue":"Suppl 1","key":"157_CR383","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.schres.2007.12.102","volume":"98","author":"R Emsley","year":"2008","unstructured":"Emsley R, Doelder PD, Schoemaker J, et al. Long-term safety of asenapine in patients with schizophrenia. Schizophr Res. 2008;98(Suppl 1):48.","journal-title":"Schizophr Res"},{"issue":"4","key":"157_CR384","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1055\/s-0030-1248313","volume":"43","author":"J Schoemaker","year":"2010","unstructured":"Schoemaker J, Naber D, Vrijland P, et al. Long-term assessment of asenapine vs. olanzapine in patients with schizophrenia or schizoaffective disorder. Pharmacopsychiatry. 2010;43(4):138\u201346.","journal-title":"Pharmacopsychiatry"},{"issue":"5","key":"157_CR385","first-page":"196","volume":"45","author":"J Schoemaker","year":"2012","unstructured":"Schoemaker J, Stet L, Vrijland P, et al. Long-term efficacy and safety of asenapine or olanzapine in patients with schizophrenia or schizoaffective disorder: an extension study. Pharmacopsychiatry. 2012;45(5):196\u2013203.","journal-title":"Pharmacopsychiatry"},{"key":"157_CR386","unstructured":"Fanapt (iloperidone) package insert. Rockville: Vanda Pharmaceuticals; 2013. http:\/\/www.pharma.us.novartis.com\/product\/pi\/pdf\/fanapt.pdf . Accessed 26 Sep 2013."},{"issue":"10","key":"157_CR387","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1007\/s40266-012-0009-0","volume":"29","author":"J Rado","year":"2012","unstructured":"Rado J, Janicak PG. Pharmacological and clinical profile of recently approved second-generation antipsychotics: implications for treatment of schizophrenia in older patients. Drugs Aging. 2012;29(10):783\u201391.","journal-title":"Drugs Aging"},{"issue":"4","key":"157_CR388","doi-asserted-by":"crossref","first-page":"249","DOI":"10.2165\/00023210-200216040-00004","volume":"16","author":"JP Kelleher","year":"2002","unstructured":"Kelleher JP, Centorrino F, Albert MJ, et al. Advances in atypical antipsychotics for the treatment of schizophrenia: new formulations and new agents. CNS Drugs. 2002;16(4):249\u201361.","journal-title":"CNS Drugs"},{"issue":"2 Suppl 1","key":"157_CR389","doi-asserted-by":"crossref","first-page":"S20","DOI":"10.1097\/JCP.0b013e318169d4ce","volume":"28","author":"AJ Cutler","year":"2008","unstructured":"Cutler AJ, Kalali AH, Weiden PJ, et al. Four-week, double-blind, placebo- and ziprasidone-controlled trial of iloperidone in patients with acute exacerbations of schizophrenia. J Clin Psychopharmacol. 2008;28(2 Suppl 1):S20\u20138.","journal-title":"J Clin Psychopharmacol"},{"issue":"12","key":"157_CR390","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1586\/ern.09.119","volume":"9","author":"AJ Cutler","year":"2009","unstructured":"Cutler AJ. Iloperidone: a new option for the treatment of schizophrenia. Expert Rev Neurother. 2009;9(12):1727\u201341.","journal-title":"Expert Rev Neurother"},{"issue":"12","key":"157_CR391","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1517\/17425255.2010.531259","volume":"6","author":"L Citrome","year":"2010","unstructured":"Citrome L. Iloperidone: chemistry, pharmacodynamics, pharmacokinetics and metabolism, clinical efficacy, safety and tolerability, regulatory affairs, and an opinion. Expert Opin Drug Metab Toxicol. 2010;6(12):1551\u201364.","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"8","key":"157_CR392","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1358\/dot.2010.46.8.1509989","volume":"46","author":"JR Bishop","year":"2010","unstructured":"Bishop JR, Bishop DL. Iloperidone for the treatment of schizophrenia. Drugs Today (Barc). 2010;46(8):567\u201379.","journal-title":"Drugs Today (Barc)"},{"issue":"4","key":"157_CR393","doi-asserted-by":"crossref","first-page":"301","DOI":"10.2146\/ajhp100079","volume":"68","author":"SA Arif","year":"2011","unstructured":"Arif SA, Mitchell MM. Iloperidone: a new drug for the treatment of schizophrenia. Am J Health Syst Pharm. 2011;68(4):301\u20138.","journal-title":"Am J Health Syst Pharm"},{"issue":"Suppl 1","key":"157_CR394","doi-asserted-by":"crossref","first-page":"19","DOI":"10.4088\/JCP.10075su1.04","volume":"72","author":"L Citrome","year":"2011","unstructured":"Citrome L. Iloperidone: a clinical overview. J Clin Psychiatry. 2011;72(Suppl 1):19\u201323.","journal-title":"J Clin Psychiatry"},{"issue":"3","key":"157_CR395","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.clinthera.2011.03.006","volume":"33","author":"BL Crabtree","year":"2011","unstructured":"Crabtree BL, Montgomery J. Iloperidone for the management of adults with schizophrenia. Clin Ther. 2011;33(3):330\u201345.","journal-title":"Clin Ther"},{"issue":"2 Suppl 1","key":"157_CR396","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.1097\/JCP.0b013e3181694f5a","volume":"28","author":"PJ Weiden","year":"2008","unstructured":"Weiden PJ, Cutler AJ, Polymeropoulos MH, et al. Safety profile of iloperidone: a pooled analysis of 6-week acute-phase pivotal trials. J Clin Psychopharmacol. 2008;28(2 Suppl 1):S12\u20139.","journal-title":"J Clin Psychopharmacol"},{"issue":"1","key":"157_CR397","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1017\/S1092852912000764","volume":"18","author":"AJ Cutler","year":"2013","unstructured":"Cutler AJ, Kalali AH, Mattingly GW, et al. Long-term safety and tolerability of iloperidone: results from a 25-week, open-label extension trial. CNS Spectr. 2013;18(1):43\u201354.","journal-title":"CNS Spectr"},{"issue":"1","key":"157_CR398","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1517\/13543784.17.1.61","volume":"17","author":"LJ Albers","year":"2008","unstructured":"Albers LJ, Musenga A, Raggi MA. Iloperidone: a new benzisoxazole atypical antipsychotic drug. Is it novel enough to impact the crowded atypical antipsychotic market? Expert Opin Investig Drugs. 2008;17(1):61\u201375.","journal-title":"Expert Opin Investig Drugs"},{"issue":"6","key":"157_CR399","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1111\/j.1742-1241.2010.02344.x","volume":"64","author":"L Citrome","year":"2010","unstructured":"Citrome L. Iloperidone redux: a dissection of the Drug Approval Package for this newly commercialised second-generation antipsychotic. Int J Clin Pract. 2010;64(6):707\u201318.","journal-title":"Int J Clin Pract"},{"issue":"11","key":"157_CR400","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1517\/14656566.2012.683174","volume":"13","author":"RS McIntyre","year":"2012","unstructured":"McIntyre RS, Cha DS, Alsuwaidan M, et al. A review of published evidence reporting on the efficacy and pharmacology of lurasidone. Expert Opin Pharmacother. 2012;13(11):1653\u20139.","journal-title":"Expert Opin Pharmacother"},{"issue":"3","key":"157_CR401","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1007\/s00213-012-2838-2","volume":"225","author":"M Ogasa","year":"2013","unstructured":"Ogasa M, Kimura T, Nakamura M, et al. Lurasidone in the treatment of schizophrenia: a 6-week, placebo-controlled study. Psychopharmacology (Berl). 2013;225(3):519\u201330.","journal-title":"Psychopharmacology (Berl)"},{"key":"157_CR402","doi-asserted-by":"crossref","first-page":"239","DOI":"10.2147\/TCRM.S12701","volume":"7","author":"L Samalin","year":"2011","unstructured":"Samalin L, Garnier M, Llorca PM. Clinical potential of lurasidone in the management of schizophrenia. Ther Clin Risk Manag. 2011;7:239\u201350.","journal-title":"Ther Clin Risk Manag"},{"issue":"5","key":"157_CR403","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/j.jpsychires.2013.01.020","volume":"47","author":"HA Nasrallah","year":"2013","unstructured":"Nasrallah HA, Silva R, Phillips D, et al. Lurasidone for the treatment of acutely psychotic patients with schizophrenia: a\u00a06-week, randomized, placebo-controlled study. J Psychiatr Res. 2013;47(5):670\u20137.","journal-title":"J Psychiatr Res"},{"key":"157_CR404","unstructured":"Latuda (prescribing information). Sunovion Pharmaceuticals Inc. http:\/\/www.latuda.com\/LatudaPrescribingInformation.pdf . Revised Dec 2012, Accessed 18 Sep 2013."},{"key":"157_CR405","doi-asserted-by":"crossref","first-page":"107","DOI":"10.2147\/DDDT.S11180","volume":"6","author":"N Yasui-Furukori","year":"2012","unstructured":"Yasui-Furukori N. Update on the development of lurasidone as a treatment for patients with acute schizophrenia. Drug Des Dev Ther. 2012;6:107\u201315.","journal-title":"Drug Des Dev Ther"},{"issue":"2","key":"157_CR406","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1111\/j.1742-1241.2010.02587.x","volume":"65","author":"L Citrome","year":"2011","unstructured":"Citrome L. Lurasidone for schizophrenia: a review of the efficacy and safety profile for this newly approved second-generation antipsychotic. Int J Clin Pract. 2011;65(2):189\u2013210.","journal-title":"Int J Clin Pract"},{"issue":"11","key":"157_CR407","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1358\/dot.2011.47.11.1708832","volume":"47","author":"RT Owen","year":"2011","unstructured":"Owen RT. Lurasidone: a new treatment option for schizophrenia. Drugs Today (Barc). 2011;47(11):807\u201316.","journal-title":"Drugs Today (Barc)"},{"issue":"1","key":"157_CR408","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s40263-012-0026-x","volume":"27","author":"M Sanford","year":"2013","unstructured":"Sanford M. Lurasidone: in the treatment of schizophrenia. CNS Drugs. 2013;27(1):67\u201380.","journal-title":"CNS Drugs"},{"issue":"6","key":"157_CR409","doi-asserted-by":"crossref","first-page":"829","DOI":"10.4088\/JCP.08m04905","volume":"70","author":"M Nakamura","year":"2009","unstructured":"Nakamura M, Ogasa M, Guarino J, et al. Lurasidone in the treatment of acute schizophrenia: a double-blind, placebo-controlled trial. J Clin Psychiatry. 2009;70(6):829\u201336.","journal-title":"J Clin Psychiatry"},{"issue":"Suppl 1","key":"157_CR410","first-page":"217","volume":"13","author":"J Cucchiaro","year":"2010","unstructured":"Cucchiaro J, Pikalov A, Ogasa M, et al. Safety of lurasidone: pooled analysis of five placebo-controlled trials in patients with schizophrenia. Int J Neuropsychopharmacol. 2010;13(Suppl 1):217.","journal-title":"Int J Neuropsychopharmacol"},{"issue":"2","key":"157_CR411","doi-asserted-by":"crossref","first-page":"170","DOI":"10.4088\/JCP.12m07992","volume":"74","author":"JP McEvoy","year":"2013","unstructured":"McEvoy JP, Citrome L, Hernandez D, et al. Effectiveness of lurasidone in patients with schizophrenia or schizoaffective disorder switched from other antipsychotics: a randomized, 6-week, open-label study. J Clin Psychiatry. 2013;74(2):170\u20139.","journal-title":"J Clin Psychiatry"},{"issue":"1\u20133","key":"157_CR412","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.schres.2013.01.009","volume":"145","author":"A Loebel","year":"2013","unstructured":"Loebel A, Cucchiaro J, Sarma K, et al. Efficacy and safety of lurasidone 80\u00a0mg\/day and 160\u00a0mg\/day in the treatment of schizophrenia: a randomized, double-blind, placebo- and active-controlled trial. Schizophr Res. 2013;145(1\u20133):101\u20139.","journal-title":"Schizophr Res"},{"key":"157_CR413","unstructured":"Hiroki O, Masakumi M, Masaaki O, et al. A prospective, 1-year, open-label, flexible dose study of lurasidone in the treatment of schizophrenia: safety, tolerability and effectiveness. Poster presented at the 164th annual meeting American Psychiatric Association, Honolulu; 2011 (Abst NR06-22)."},{"issue":"5","key":"157_CR414","doi-asserted-by":"crossref","first-page":"507","DOI":"10.4088\/JCP.12m08084","volume":"74","author":"SM Stahl","year":"2013","unstructured":"Stahl SM, Cucchiaro J, Simonelli D, et al. Effectiveness of lurasidone for patients with schizophrenia following 6\u00a0weeks of acute treatment with lurasidone, olanzapine, or placebo: a 6-month, open-label, extension study. J Clin Psychiatry. 2013;74(5):507\u201315.","journal-title":"J Clin Psychiatry"},{"key":"157_CR415","unstructured":"Yu WP, Detraux J, Sweers K, van Winkel R, Correll CU, De Hert M. Effectiveness and safety of asenapine, iloperidone, lurasidone, and paliperidone in the short-term treatment of schizophrenia and bipolar disorder: a systematic review and exploratory meta-analysis of randomized placebo-controlled trials (unpublished report)."},{"issue":"7","key":"157_CR416","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1016\/j.pnpbp.2003.09.006","volume":"27","author":"HJ M\u00f6ller","year":"2003","unstructured":"M\u00f6ller HJ. Amisulpride: limbic specificity and the mechanism of antipsychotic atypicality. Prog Neuropsychopharmacol Biol Psychiatry. 2003;27(7):1101\u201311.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"issue":"1","key":"157_CR417","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1124\/jpet.111.190702","volume":"342","author":"X Langlois","year":"2012","unstructured":"Langlois X, Megens A, Lavreysen H, et al. Pharmacology of JNJ-37822681, a specific and fast-dissociating D2 antagonist for the treatment of schizophrenia. J Pharmacol Exp Ther. 2012;342(1):91\u2013105.","journal-title":"J Pharmacol Exp Ther"},{"issue":"3","key":"157_CR418","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1124\/jpet.102.035303","volume":"302","author":"S Kapur","year":"2002","unstructured":"Kapur S, Langlois X, Vinken P, et al. The differential effects of atypical antipsychotics on prolactin elevation are explained by their differential blood\u2013brain disposition: a pharmacological analysis in rats. J Pharmacol Exp Ther. 2002;302(3):1129\u201334.","journal-title":"J Pharmacol Exp Ther"},{"issue":"11","key":"157_CR419","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1016\/j.euroneuro.2012.11.014","volume":"23","author":"A Bartolomeis De","year":"2013","unstructured":"De Bartolomeis A, Marmo F, Buonaguro EF, et al. Imaging brain gene expression profiles by antipsychotics: region-specific action of amisulpride on postsynaptic density transcripts compared to haloperidol. Eur Neuropsychopharmacol. 2013;23(11):1516\u201329.","journal-title":"Eur Neuropsychopharmacol"},{"issue":"5","key":"157_CR420","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1017\/S1461145711000824","volume":"15","author":"L Carboni","year":"2012","unstructured":"Carboni L, Negri M, Michielin F, Bertani S, Fratte SD, Oliosi B, Cavanni P. Slow dissociation of partial agonists from the D2 receptor is linked to reduced prolactin release. Int J Neuropsychopharmacol. 2012;15(5):645\u201356.","journal-title":"Int J Neuropsychopharmacol"},{"issue":"3","key":"157_CR421","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/s00213-004-1826-6","volume":"175","author":"RA Bressan","year":"2004","unstructured":"Bressan RA, Erlandsson K, Spencer EP, et al. Prolactinemia is uncoupled from central D2\/D3 dopamine receptor occupancy in amisulpride treated patients. Psychopharmacology (Berl). 2004;175(3):367\u201373.","journal-title":"Psychopharmacology (Berl)"},{"issue":"2","key":"157_CR422","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1176\/ajp.156.2.286","volume":"156","author":"S Kapur","year":"1999","unstructured":"Kapur S, Zipursky R, Remington G. Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia. Am J Psychiatry. 1999;156(2):286\u201393.","journal-title":"Am J Psychiatry"},{"issue":"1","key":"157_CR423","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.coph.2011.02.007","volume":"11","author":"H Meltzer","year":"2011","unstructured":"Meltzer H, Massey B. The role of serotonin receptors in the action of atypical antipsychotic drugs. Curr Opin Pharmacol. 2011;11(1):59\u201367.","journal-title":"Curr Opin Pharmacol"},{"issue":"5","key":"157_CR424","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1097\/FPC.0b013e328329a60f","volume":"19","author":"CA Calarge","year":"2009","unstructured":"Calarge CA, Ellingrod VL, Acion L, et al. Variants of the dopamine D2 receptor gene and risperidone-induced hyperprolactinemia in children and adolescents. Pharmacogenet Genomics. 2009;19(5):373\u201382.","journal-title":"Pharmacogenet Genomics"},{"issue":"1\u20132","key":"157_CR425","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.psychres.2009.06.014","volume":"175","author":"JP Houston","year":"2010","unstructured":"Houston JP, Fijal B, Heinloth AN, et al. Genetic associations of prolactin increase in olanzapine\/fluoxetine combination-treated patients. Psychiatry Res. 2010;175(1\u20132):171\u20132.","journal-title":"Psychiatry Res"},{"issue":"2 Suppl","key":"157_CR426","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1177\/0269881107088438","volume":"22","author":"SM Smith","year":"2008","unstructured":"Smith SM. The impact of hyperprolactinaemia on sexual function in patients with psychosis. J. Psychopharmacol. 2008;22(2 Suppl):63\u20139.","journal-title":"J. Psychopharmacol"},{"issue":"4","key":"157_CR427","first-page":"a534","volume":"5","author":"U Vyas","year":"2012","unstructured":"Vyas U. Risk of breast cancer due to hyperprolactinemia caused by antipsychotics (neuroleptics). BJMP. 2012;5(4):a534.","journal-title":"BJMP"},{"issue":"3","key":"157_CR428","doi-asserted-by":"crossref","first-page":"153","DOI":"10.5534\/wjmh.2012.30.3.153","volume":"30","author":"YW Park","year":"2012","unstructured":"Park YW, Kim Y, Lee JH. Antipsychotic-induced sexual dysfunction and its management. World J Mens Health. 2012;30(3):153\u20139.","journal-title":"World J Mens Health"},{"issue":"6","key":"157_CR429","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1097\/JCP.0b013e3181faf0e3","volume":"30","author":"MA Rettenbacher","year":"2010","unstructured":"Rettenbacher MA, Hofer A, Ebenbichler C, et al. Prolactin levels and sexual adverse effects in patients with schizophrenia during antipsychotic treatment. J Clin Psychopharmacol. 2010;30(6):711\u20135.","journal-title":"J Clin Psychopharmacol"},{"issue":"12","key":"157_CR430","doi-asserted-by":"crossref","first-page":"2816","DOI":"10.1111\/j.1743-6109.2008.00859.x","volume":"5","author":"J Westheide","year":"2008","unstructured":"Westheide J, Cvetanovska G, Albrecht C, et al. Prolactin, subjective well-being and sexual dysfunction: an open label observational study comparing quetiapine with risperidone. J Sex Med. 2008;5(12):2816\u201326.","journal-title":"J Sex Med"},{"key":"157_CR431","doi-asserted-by":"crossref","unstructured":"De Hert M, Detraux J. Novel and newly approved antipsychotics, serum prolactin levels and sexual dysfunctions: a critical literature review. Expert Opin Drug Saf. 2014 (in press).","DOI":"10.1517\/14740338.2014.906579"},{"key":"157_CR432","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1192\/bjp.bp.111.101220","volume":"201","author":"TR Marques","year":"2012","unstructured":"Marques TR, Smith S, Bonaccorso S, et al. Sexual dysfunction in people with prodromal or first-episode psychosis. Br J Psychiatry. 2012;201:131\u20136.","journal-title":"Br J Psychiatry"},{"issue":"2","key":"157_CR433","doi-asserted-by":"crossref","first-page":"171","DOI":"10.2165\/00002018-200730020-00006","volume":"30","author":"B Takkouche","year":"2007","unstructured":"Takkouche B, Montes-Mart\u00ednez A, Gill SS, et al. Psychotropic medications and the risk of fracture: a meta-analysis. Drug Saf. 2007;30(2):171\u201384.","journal-title":"Drug Saf"},{"key":"157_CR434","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1192\/bjp.bp.106.023671","volume":"190","author":"L Howard","year":"2007","unstructured":"Howard L, Kirkwood G, Leese M. Risk of hip fracture in patients with a history of schizophrenia. Br J Psychiatry. 2007;190:129\u201334.","journal-title":"Br J Psychiatry"},{"issue":"6","key":"157_CR435","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1016\/j.bone.2005.07.005","volume":"37","author":"GW Hugenholtz","year":"2005","unstructured":"Hugenholtz GW, Heerdink ER, van Staa TP, et al. Risk of hip\/femur fractures in patients using antipsychotics. Bone. 2005;37(6):864\u201370.","journal-title":"Bone"},{"issue":"6","key":"157_CR436","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1007\/s00198-005-0065-y","volume":"17","author":"P Vestergaard","year":"2006","unstructured":"Vestergaard P, Rejnmark L, Mosekilde L. Anxiolytics, sedatives, antidepressants, neuroleptics and the risk of fracture. Osteoporos Int. 2006;17(6):807\u201316.","journal-title":"Osteoporos Int"},{"issue":"4","key":"157_CR437","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1097\/00001648-199807000-00012","volume":"9","author":"H Jacqmin-Gadda","year":"1998","unstructured":"Jacqmin-Gadda H, Fourrier A, Commenges D, et al. Risk factors for fractures in the elderly. Epidemiology. 1998;9(4):417\u201323.","journal-title":"Epidemiology"},{"issue":"9","key":"157_CR438","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1093\/oxfordjournals.aje.a009714","volume":"148","author":"Z Guo","year":"1998","unstructured":"Guo Z, Wills P, Viitanen M, et al. Cognitive impairment, drug use, and the risk of hip fracture in persons over 75\u00a0years old: a community-based prospective study. Am J Epidemiol. 1998;148(9):887\u201392.","journal-title":"Am J Epidemiol"},{"issue":"4","key":"157_CR439","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1097\/JCP.0b013e31817d5943","volume":"28","author":"JM Bolton","year":"2008","unstructured":"Bolton JM, Metge C, Lix L, et al. Fracture risk from psychotropic medications: a population-based analysis. J Clin Psychopharmacol. 2008;28(4):384\u201391.","journal-title":"J Clin Psychopharmacol"},{"issue":"5","key":"157_CR440","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1097\/YCO.0b013e328355e1ac","volume":"25","author":"T Kishimoto","year":"2012","unstructured":"Kishimoto T, De Hert M, Carlson HE, et al. Osteoporosis and fracture risk in people with schizophrenia. Curr Opin Psychiatry. 2012;25(5):415\u201329.","journal-title":"Curr Opin Psychiatry"},{"issue":"2 Suppl","key":"157_CR441","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1177\/0269881107087955","volume":"22","author":"MK Javaid","year":"2008","unstructured":"Javaid MK, Holt RI. Understanding osteoporosis. J Psychopharmacol. 2008;22(2 Suppl):38\u201345.","journal-title":"J Psychopharmacol"},{"issue":"1","key":"157_CR442","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1002\/hup.1265","volume":"27","author":"MP Crews","year":"2012","unstructured":"Crews MP, Howes OD. Is antipsychotic treatment linked to low bone mineral density and osteoporosis? A review of the evidence and the clinical implications. Hum Psychopharmacol. 2012;27(1):15\u201323.","journal-title":"Hum Psychopharmacol"},{"issue":"15","key":"157_CR443","doi-asserted-by":"crossref","first-page":"4810","DOI":"10.1158\/0008-5472.CAN-13-0665","volume":"73","author":"SS Tworoger","year":"2013","unstructured":"Tworoger SS, Eliassen AH, Zhang X, Qian J, Sluss PM, Rosner BA, Hankinson SE. A 20-year prospective study of plasma prolactin as a risk marker of breast cancer development. Cancer Res. 2013;73(15):4810\u20139.","journal-title":"Cancer Res"},{"issue":"1","key":"157_CR444","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/jat.1772","volume":"32","author":"PW Harvey","year":"2012","unstructured":"Harvey PW. Hypothesis: prolactin is tumorigenic to human breast: dispelling the myth that prolactin-induced mammary tumors are rodent-specific. J Appl Toxicol. 2012;32(1):1\u20139.","journal-title":"J Appl Toxicol"},{"issue":"Suppl 2","key":"157_CR445","doi-asserted-by":"crossref","first-page":"S195","DOI":"10.4103\/2230-8210.104038","volume":"16","author":"BK Sethi","year":"2012","unstructured":"Sethi BK, Chanukya GV, Nagesh VS. Prolactin and cancer: Has the orphan finally found a home? Indian J Endocrinol Metab. 2012;16(Suppl 2):S195\u20138.","journal-title":"Indian J Endocrinol Metab"},{"issue":"9","key":"157_CR446","first-page":"2703","volume":"38","author":"S Wagner","year":"1978","unstructured":"Wagner S, Mantel N. Breast cancer at a psychiatric hospital before and after the introduction of neuroleptic agents. Cancer Res. 1978;38(9):2703\u20138.","journal-title":"Cancer Res"},{"issue":"8","key":"157_CR447","first-page":"785","volume":"76","author":"S Kanhouwa","year":"1984","unstructured":"Kanhouwa S, Gowdy JM, Solomon JD. Phenothiazines and breast cancer. J Natl Med Assoc. 1984;76(8):785\u20138.","journal-title":"J Natl Med Assoc"},{"issue":"8","key":"157_CR448","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1093\/oxfordjournals.aje.a010091","volume":"150","author":"JP Kelly","year":"1999","unstructured":"Kelly JP, Rosenberg L, Palmer JR, et al. Risk of breast cancer according to use of antidepressants, phenothiazines, and antihistamines. Am J Epidemiol. 1999;150(8):861\u20138.","journal-title":"Am J Epidemiol"},{"issue":"2","key":"157_CR449","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1007\/s10549-011-1506-2","volume":"129","author":"L Azoulay","year":"2011","unstructured":"Azoulay L, Yin H, Renoux C, et al. The use of atypical antipsychotics and the risk of breast cancer. Breast Cancer Res Treat. 2011;129(2):541\u20138.","journal-title":"Breast Cancer Res Treat"}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40263-014-0157-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-014-0157-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-014-0157-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,25]],"date-time":"2024-05-25T07:53:35Z","timestamp":1716623615000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40263-014-0157-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,3,28]]},"references-count":449,"alternative-id":["157"],"URL":"https:\/\/doi.org\/10.1007\/s40263-014-0157-3","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,3,28]]}}}